

## Research paper

# Sex matters: Differences in prodromes, clinical and neuropsychological features in individuals with a first episode mania or psychosis<sup>☆</sup>

Roberto Palacios-Garran<sup>a,b,c,1</sup>, Silvia Amoretti<sup>a,b,d,e,f,1</sup>, Maria Serra-Navarro<sup>a,b</sup>, Carla Torrent<sup>a,b</sup>, Marina Garriga<sup>a,b</sup>, Natalia E. Fares-Otero<sup>a,b</sup>, Maria Sagué-Vilavella<sup>a,b</sup>, Santiago Madero<sup>b,d</sup>, M. Florencia Forte<sup>a,b</sup>, Laura Montejo<sup>a,b</sup>, Pilar Salgado-Pineda<sup>g</sup>, Irene Montoro<sup>h</sup>, Vanessa Sánchez-Gistau<sup>h</sup>, Edith Pomarol-Clotet<sup>g</sup>, Giulia Menculini<sup>i</sup>, Alfonso Tortorella<sup>i</sup>, Isabella Pacchiarotti<sup>a,b</sup>, Clemente Garcia-Rizo<sup>b,d</sup>, Josep Antoni Ramos-Quiroga<sup>e,f</sup>, Anabel Martínez-Arán<sup>a,b,\*</sup>, Eduard Vieta<sup>a,b,\*</sup>, Norma Verdolini<sup>a,b,j</sup>

<sup>a</sup> Bipolar and Depressive Disorders Unit, Hospital Clínic, Institute of Neuroscience (UB Neuro), Department of Medicine, Facultat de Medicina i Ciències de la Salut, University of Barcelona, Fundació Clínic per la Recerca Biomèdica-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FCRB-IDIBAPS), CIBERSAM-ISCIII, Barcelona, Catalonia, Spain

<sup>b</sup> Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain

<sup>c</sup> Hospital Universitario Jerez de la Frontera, University of Cádiz, Cádiz, Spain

<sup>d</sup> Barcelona Clinic Schizophrenia Unit, Hospital Clínic de Barcelona, Departament de Medicina, Institut de Neurociències (UBNeuro), Universitat de Barcelona (UB), FCRB-IDIBAPS), CIBERSAM-ISCIII, Barcelona, Spain

<sup>e</sup> Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), CIBERSAM-ISCIII, Barcelona, Catalonia, Spain

<sup>f</sup> Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

<sup>g</sup> FIDMAG Germanes Hospitalàries Research Foundation, CIBERSAM-ISCIII, Sant Boi de Llobregat, Barcelona, Spain

<sup>h</sup> Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, CIBERSAM-ISCIII, Reus, Tarragona, Spain

<sup>i</sup> Department of Psychiatry, University of Perugia, Perugia, Italy

<sup>j</sup> Local Health Unit Umbria 1, Department of Mental Health, Mental Health Center of Perugia, Perugia, Italy

## ARTICLE INFO

## Keywords:

First episode mania  
First episode psychosis  
Prodromes  
Bipolar disorder  
Emotional intelligence  
Early psychosis  
Sex differences

## ABSTRACT

**Objective:** This study was aimed at identifying sex differences in patients presenting a first episode mania (FEM) or psychosis (FEP) to help shaping early treatment strategies focused on sex differences.

**Methods:** Patients with a FEM or FEP underwent a clinical, neuropsychological (neurocognitive functions and emotional intelligence) and functional assessment. Performance on those variables was compared between groups through general linear model, with sex and group (FEM vs FEP) as main effects and group by sex interactions.

**Results:** The total sample included 113 patients: FEM = 72 (45.83 % females) and FEP = 41 (46.34 % females). There were significant main effects for group (not for sex) for most of the clinical features (depressive, negative and positive symptoms) and psychosocial functioning ( $\chi^2 = 8.815$ ,  $p = 0.003$ ). As for neuropsychological performance, there were significant main effects for sex and group. Females performed better than males in verbal memory ( $\chi^2 = 9.038$ ,  $p = 0.003$ ) and obtained a higher emotional intelligence quotient ( $\chi^2 = 13.20$ ,  $p < 0.001$ ). On the contrary, males obtained better results in working memory ( $\chi^2 = 7.627$ ,  $p = 0.006$ ). FEP patients significantly underperformed FEM patients in most cognitive domains. There were significant group by sex interactions for few neuropsychological variables, namely processing speed ( $\chi^2 = 4.559$ ,  $p = 0.033$ ) and verbal fluency ( $\chi^2 = 8.913$ ,  $p = 0.003$ ).

<sup>☆</sup> Location of work and address for reprints: Bipolar and Depressive Disorders Unit, Hospital Clínic, University of Barcelona, Institute of Neuroscience, IDIBAPS, CIBERSAM-ISCIII, 170 Villarroel st, 12-0, 08036, Barcelona, Catalonia, Spain.

\* Corresponding authors at: Bipolar and Depressive Disorders Unit, Hospital Clínic, University of Barcelona, Institute of Neuroscience, IDIBAPS, CIBERSAM-ISCIII, 170 Villarroel st, 12-0, 08036 Barcelona, Catalonia, Spain.

E-mail addresses: [AMARTIAR@clinic.cat](mailto:AMARTIAR@clinic.cat) (A. Martínez-Arán), [EVIIETA@clinic.cat](mailto:EVIIETA@clinic.cat) (E. Vieta).

<sup>1</sup> The first two authors contributed equally to this work.

*Limitations:* Differences between sexes were evaluated, but the influence of gender was not considered. Retrospective evaluation of prodromes and substance use. No healthy control group comparator.

*Conclusion:* The main finding is the presence of significant sex effect and group by sex interaction on specific neurocognitive cognition and emotional intelligence measures. Tailored sex-based early treatment strategies might be implemented.

## 1. Introduction

Sex can make a difference in the characteristics of many psychiatric disorders. It can affect incidence and prevalence but also other clinical features such as age of onset, severity, and clinical course or treatment response (Pinares-Garcia et al., 2018). Sex differences are based on genetics, anatomy, and physiology, representing a biological construct. This may be linked with sex hormones (Gogos et al., 2019) and dysregulations in the hypothalamic-pituitary-adrenal axis (Bangasser and Valentino, 2014), and appear in various psychiatric disorders (Pinares-Garcia et al., 2018).

As for schizophrenia (SCZ), previous studies highlighted a slightly more frequent prevalence in males than in females, with a 1.4-fold increase (Kahn et al., 2015). The age of onset of the first episode psychosis (FEP) is lower in males, with a peak of incidence at around 20–24 years old, meanwhile in females it occurs 5 or more years later (Kahn et al., 2015). Sex differences in the clinical presentation have been described, with higher prevalence of affective symptoms in females (Ochoa et al., 2012). On the contrary, negative symptoms, disorganization and substance abuse were found to be more prevalent in males (Køster et al., 2008; Ochoa et al., 2012). In general, SCZ symptoms seem to be more severe in males, and sex differences impact also on disease progression and prognosis (Murray and Castle, 1991). In particular, males present longer and more frequent hospitalizations and less responsiveness to antipsychotics (Gogos et al., 2019; Szymanski et al., 1995; Usall et al., 2003). Conversely, rates of remission and recovery are higher in females (Carpiniello et al., 2012).

As for bipolar disorder (BD) type I, the prevalence is similar in males and females (Vieta et al., 2018). The age of onset is around 20 years across both sexes (Vieta et al., 2018), although some studies have reported that females may be faintly older than males (Diflorio and Jones, 2010; Gogos et al., 2019; Kawa et al., 2005). In general, females have a higher predisposition to present a depressive onset (Viguera et al., 2001), more depressive episodes (Altshuler et al., 2010; Bräunig et al., 2009) and to present refractory depression (Nivoli et al., 2011). Few studies also reported increased rates of rapid cycling (Baldassano et al., 2005; Robb et al., 1998) and mixed symptoms (Gogos et al., 2019; Suppes et al., 2005) whilst males would be more prone to mania, present more frequently mania as their first episode and report higher rates of unipolar mania (Diflorio and Jones, 2010). Similarly to SCZ, males with BD present more comorbid substance use disorders than females whilst females with BD had more lifetime comorbid eating disorders, post-traumatic stress disorder (Baldassano et al., 2005; Suominen et al., 2009).

Sex differences in neurocognition and psychosocial functioning have been studied in both SCZ and BD. In SCZ, findings are controversial. Several studies indicate higher levels of cognitive functioning in females, especially in language, executive function, and memory domains (Goldstein et al., 1998; Goldstein et al., 1994) whilst males tend to have more cognitive impairment (Mendrek and Mancini-Marie, 2016; Zhang et al., 2017). These differences were found even at FEP (Pu et al., 2019). Nevertheless, other studies have exposed worse cognitive functioning in females than in males (Brébion et al., 2018; Leger and Neill, 2016; Lewine et al., 1996). Other studies found no sex differences in the assessment of cognitive impairment (Bozikas et al., 2010) in chronic SCZ patients or in patients with a FEP (Zhang et al., 2012).

In BD, a significant sex effect on specific neurocognitive measures related to working and verbal memory domains has been found

(Baldassano et al., 2005). Specifically, males performed better than females in working memory tasks, whereas females outperformed males in verbal learning and memory recognition tasks (Solé et al., 2022).

Sex differences have been assessed also in emotional intelligence. As for patients presenting a first episode mania (FEM), the Emotional Intelligence Quotient (EIQ) was positively associated with female sex and verbal memory performance (Varo et al., 2022). On the contrary, no significant differences in emotional intelligence between males and females were found in patients presenting a FEP (Casado-Ortega et al., 2021). Interestingly, while the EIQ did not differ in FEM in comparison with healthy controls (HC) and BD (Solé et al., 2022), emotional intelligence (EI) was found to be already impaired in FEP patients at onset, representing this impairment a stable pattern and a relevant feature of SCZ (Green et al., 2012).

Both SCZ and BD are frequently preceded by the emergence of prodromal symptoms that can typically last months or years (Barajas et al., 2017; Conroy et al., 2018; Kahn et al., 2015). Sex differences in SCZ are present in prodromes too, with males displaying poorer premorbid functioning than females, including greater social withdrawal, isolation, and poor self-care before the FEP (Mendrek and Mancini-Marie, 2016). There is less information about sex differences during the BD prodrome, particularly during the prodrome to a FEM. Characterizing the particular features of each sex prodrome for both BD and SCZ might help recognizing patients with a higher risk of developing a first episode. Similarly, identifying the clinical variables, psychosocial functioning and neurocognitive characteristics that differed in males and females might help shaping specific tailored early treatment strategies. Our main aim is to identify sex differences in patients that experienced their first FEM (or FEP), with onset in late adolescence or adulthood, and to compare the specific features that characterized males (or females) with a FEM (or a FEP). We selected participants aged 18 and above to focus on the adult onset of the disorder, which presents distinct clinical characteristics from the earlier presentation. Finally, the specific effect exerted by the combination of sex (female vs male) and type of first episode (FEP vs FEM) has been explored to understand their potential interaction on clinical and neuropsychological variables.

## 2. Material and methods

### 2.1. Participants

The cohort of the present cross-sectional study has been drawn from the “Prodromes and Predictors in First Episode Mania and Psychosis” – ProPreF project, a two year-study focused on prodromes, predictors and longitudinal outcomes in patients presenting a FEM/FEP, described elsewhere (Verdolini et al., 2022). This multicentric study included the Bipolar and Depressive Disorders Unit of IDIBAPS-Hospital Clinic in Barcelona, FIDMAG Research Foundation and the Institut Pere Mata. All centers are members of the Spanish Network Center for Biomedical Research in Mental Health (CIBERSAM) (Salagre et al., 2019).

Subjects in the early stages of the disease that presented a FEP or FEM were recruited. The inclusion criteria for patients were: (I) age between 18 and 45 years at the time of first evaluation; (II) having experienced their FEP/FEM along the previous four years; (III) had their FEP/FEM at 18 years old or later (IV) being in full or partial clinical remission (i.e., after discharge from the hospital) (Verdolini et al., 2022).

Exclusion criteria were the presence of (I) intellectual disability

(defined as intelligence quotient [IQ] <70); (II) any medical condition affecting neuropsychological performance; (III) alcohol/substance dependence in the 12 months previously study inclusion (excluding caffeine and tobacco); (IV) having received electroconvulsive therapy in the year before participation.

The study was carried out following the latest version of the Declaration of Helsinki and it was reviewed by the ethical committee of the three recruiting centers. Participants gave written informed consent prior to study enrollment.

## 2.2. Procedures

At the time of evaluation, a trained researcher assessed clinical diagnosis of the patients with the semi-structured interview based on the Structured Clinical Interview for DSM Disorders (SCID-I-II) (First and Gibbon, 2004) and diagnoses were confirmed according to DSM-5 criteria (American Psychiatric Association, 2013). Patients meeting the DSM-5 A-D criteria for a manic episode, were categorized as a FEM. Patients presenting at least two of the five symptoms of criterion A for a DSM-5 psychotic disorder and not experienced the DSM-5 A-D criteria for a manic episode, were categorized as a FEP.

The presence of a full FEP or FEM was evaluated by at least two investigators and an agreement was reached on the diagnosis. The diagnosis was based on the summaries of the patients' files, the life charts of psychotic and mood episodes and the assessment of the clinical presentation at first inpatient hospitalization or mental health service presentation.

All assessments were performed by a trained psychiatrist or psychologist. At baseline, all patients underwent a clinical and neuropsychological assessment when they were stable or in partial remission.

## 2.3. Socio-demographic information

Socio-demographic data (i.e., age, educational level, working status) were collected and stored in an electronic data repository.

## 2.4. Clinical assessment

Clinical symptoms at the time of evaluation were assessed with the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), the Young Mania Rating Scale (YMRS) (Young et al., 1978) and the Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979). A total score was obtained from each scale. Higher scores correspond to greater severity.

Psychosocial functioning was assessed through the Functional Assessment Short Test (FAST) (Rosa et al., 2007). The FAST assessment refers to the last 15 days and comprises 24 items, which are divided in 6 specific areas of functioning: 1) Autonomy; 2) Occupational functioning; 3) Cognitive functioning; 4) Financial issues; 5) Interpersonal relationships; and 6) Leisure Time. Items can be rated using a 4-point scale, from 0 = no difficulty to 3 = severe difficulty. The global score is calculated by summing up all the scores of each item, ranging from 0 to 72, resulting in a measure of disability where higher scores refer to more serious difficulties.

## 2.5. Prodromal symptoms

Patients and their caregivers, if they were available, were inquired to retrospectively report prodromal symptoms' duration and type. First, we explained psychosis in clear language. We then provided the patient with the date of their first hospitalization or first contact with the mental health service in order to set a time point for diagnosis. Following this, patients were asked when they first experienced changes in behavior or other prodromal symptoms. During the interview, we used a timeline and asked for important dates in the life of the patients' lives to help with the recall process. Trained evaluators conducted a semi-structured

interview with the Bipolar Prodrome Symptom Scale-Retrospective (BPSS-R) (Correll et al., 2007), focusing mainly on prodromic symptoms' type, frequency, and duration. Prodromal symptoms' severity and frequency were rated on an ordinal scale from 0 (absent) to 4 (static lifetime or character trait) (Correll et al., 2014; Correll et al., 2007). Any prodromal symptom independent of severity, frequency, and any episode occurring before the FEM/FEP in the lifetime of the patient, was assessed in the interview. Only those symptoms occurring within 3 years and 1 month before the first full episode displaying at least moderate severity were considered in the analyses (Correll et al., 2014; Correll et al., 2007; Kafali et al., 2019). In addition, symptoms with a frequency score of 4 (static lifetime or character trait) were not included as they are not considered part of the proximal prodrome (Correll et al., 2014, Correll et al., 2007).

Furthermore, information on the use of cannabis and alcohol during the prodromal phase was obtained. The Premorbid Adjustment Scale (PAS) (Cannon-Spoor et al., 1982) was used to assess the achievement of developmental goals during the childhood and adolescent periods in the participant's lives (Cannon-Spoor et al., 1982).

## 2.6. Neurocognitive functioning

The neuropsychological battery measured the following neurocognitive domains: 1. Estimated intelligence quotient (IQ), assessed with the Wechsler Adult Intelligence Scale (WAIS-III) (Wechsler, 1955) vocabulary subtest; 2. Working memory index of the WAIS-III, calculated by the performance on the Digit Span, Arithmetic and Letter-Number Sequencing subtests; 3. Processing speed index of the WAIS-III calculated by the Digit Symbol and Symbol Search subtests; 4. Verbal learning and memory, assessed with the California Verbal Learning Test (CVLT) (Delis et al., 1993); 5. Logical memory, evaluated using the Wechsler Memory Scale, 3rd edition (WMS-III) (Wechsler, 1997); 6. measures of executive functions, evaluated using the Wisconsin Card Sorting Test (WCST) (Berg, 1948). Sustained attention, tested with the Continuous Performance Test-II (CPT-II), version 5 (Conners, 2005); 8. Visual memory: the total score of the immediate recall of Rey-Osterrieth Complex Figure (ROCF) test (Osterrieth, 1944); and 9. Verbal fluency (phonemic and semantic), assessed with the Controlled Oral Word Association Test (COWAT) (Benton, 1967).

Higher scores correspond to better performance in all cognitive domains except for sustained attention.

## 2.7. Emotional intelligence assessment

Emotional Intelligence (EI) was evaluated using the Spanish version of the Mayer-Salovey-Caruso Intelligence Test (MSCEIT), V2.0 (Mayer et al., 2003). This instrument consists of 141 items and provides eight task scores that measure the four branches of EI: 1. Perceiving Emotions: to recognize and to appraise emotions accurately; 2. Facilitating Emotions: to access or generate feelings when they facilitate thoughts; 3. Understanding Emotions: to understand complex emotions and how emotions transition from one stage to another, to recognize the causes of emotions, and to understand relationships among emotions; 4. Managing Emotions: to stay aware of one's emotions, and to solve emotion-laden problems. The Perceiving Emotions and Facilitating Emotions branches are assigned to the Experiential Area, while the Understanding Emotions and Managing Emotions branches are assigned to the Strategic Area. The test provides an overall score, the EIQ, and also scores in the two areas, in the four branches and in each of the specific tasks. Lower scores indicate poorer performance in EI. The average range of EIQ is 100, with a standard deviation (SD) of 15.

All cognitive and emotional scores were standardized with respect to the subject's age, sex and/or educational level according to standardized normative data found in the test manual.

**Table 1**  
Sex differences in FEM.

| Prodromal phase                                      | Groups                |                       | Statistics                             |
|------------------------------------------------------|-----------------------|-----------------------|----------------------------------------|
|                                                      | F-FEM( <i>n</i> = 33) | M-FEM( <i>n</i> = 39) | <i>t</i> or $\chi^2$ , <i>p</i> -value |
| Alcohol use (n, %)                                   |                       |                       | 8.003, <b>0.045</b>                    |
| No                                                   | 15, 53.1              | 10, 40                |                                        |
| <1 unit/week                                         | 5, 16.1               | 3, 8.1                |                                        |
| 1–5 units/week                                       | 9, 29                 | 13, 35.1              |                                        |
| >5 units/week                                        | 2, 6.5                | 11, 29.8              |                                        |
| Cannabis use (n, %)                                  |                       |                       | 13.698, <b>0.02</b>                    |
| No                                                   | 17, 53.1              | 8, 32                 |                                        |
| <1 cig/week                                          | 0                     | 3, 8.1                |                                        |
| 1–5 cig/week                                         | 9, 28.1               | 6, 16.2               |                                        |
| >5 cig/week                                          | 6, 18.8               | 20, 54.1              |                                        |
| Prodromal symptoms                                   |                       |                       |                                        |
| Concentration difficulties, yes (n, %)               | 7, 21.2               | 18, 46.2              | 4.906, <b>0.046</b>                    |
| Irritability, yes (n, %)                             | 18, 54.5              | 10, 25.6              | 6.284, <b>0.016</b>                    |
| Clinical variables                                   |                       |                       |                                        |
| MADRS (mean $\pm$ SD)                                | 6.28 $\pm$ 6.065      | 5.97 $\pm$ 5.325      | 0.223, 0.824                           |
| YMRS (mean $\pm$ SD)                                 | 1.39 $\pm$ 1.694      | 2.13 $\pm$ 2.931      | –1.27, 0.208                           |
| PANSS Total Score (mean $\pm$ SD)                    | 40.55 $\pm$ 9.504     | 41.18 $\pm$ 11.461    | –0.257, 0.208                          |
| PANSS positive symptoms (mean $\pm$ SD)              | 7.48 $\pm$ 1.121      | 8.21 $\pm$ 2.549      | –1.512, 0.135                          |
| PANSS negative symptoms (mean $\pm$ SD)              | 10.39 $\pm$ 4.387     | 10.37 $\pm$ 5.17      | 0.022, 0.982                           |
| PANSS general psychopathology (mean $\pm$ SD)        | 22.67 $\pm$ 6.06      | 22.61 $\pm$ 5.833     | 0.043, 0.966                           |
| FAST Total Score (mean $\pm$ SD)                     | 15.36 $\pm$ 11.48     | 20.41 $\pm$ 14.649    | –1.611, 0.112                          |
| FAST autonomy (mean $\pm$ SD)                        | 1.82 $\pm$ 2.007      | 2.72 $\pm$ 3.095      | –1.425, 0.159                          |
| FAST working functioning (mean $\pm$ SD)             | 5.64 $\pm$ 5.6        | 7.95 $\pm$ 6.018      | –1.663, 0.101                          |
| FAST cognitive functioning (mean $\pm$ SD)           | 2.85 $\pm$ 2.347      | 3.51 $\pm$ 2.978      | –1.043, 0.301                          |
| FAST finances (mean $\pm$ SD)                        | 0.18 $\pm$ 0.584      | 0.54 $\pm$ 1.282      | –1.476, 0.145                          |
| FAST relationships (mean $\pm$ SD)                   | 2.82 $\pm$ 3.147      | 3.89 $\pm$ 3.985      | –1.257, 0.213                          |
| FAST leisure (mean $\pm$ SD)                         | 2.06 $\pm$ 2.061      | 1.86 $\pm$ 1.858      | 0.415, 0.679                           |
| PAS (mean $\pm$ SD)                                  | 11.12 $\pm$ 8.069     | 12.49 $\pm$ 7.301     | –0.747, 0.457                          |
| Neuropsychological variables                         |                       |                       |                                        |
| Intellectual quotient (mean $\pm$ SD)                | 100.41 $\pm$ 10.762   | 108.29 $\pm$ 13.612   | –2.494, <b>0.016</b>                   |
| Working memory (mean $\pm$ SD)                       | 86.52 $\pm$ 11.956    | 100.27 $\pm$ 14.786   | –3.876, <b>&lt;0.001</b>               |
| Processing speed (mean $\pm$ SD)                     | 99.15 $\pm$ 16.868    | 101.71 $\pm$ 16.939   | –0.576, 0.567                          |
| Verbal memory (mean $\pm$ SD)                        | 234.765 $\pm$ 43.559  | 220.272 $\pm$ 53.606  | 1.096, 0.278                           |
| Logical memory (mean $\pm$ SD)                       | 209.778 $\pm$ 36.982  | 205.538 $\pm$ 47.662  | 0.362, 0.719                           |
| Executive function (mean $\pm$ SD)                   | 134.876 $\pm$ 23.947  | 137.818 $\pm$ 22.345  | –0.476, 0.636                          |
| Sustained attention (mean $\pm$ SD)                  | 133.298 $\pm$ 15.611  | 127.277 $\pm$ 10.95   | 1.593, 0.119                           |
| Visual memory (mean $\pm$ SD)                        | 56.95 $\pm$ 12.536    | 56.28 $\pm$ 6.654     | 0.249, 0.815                           |
| Verbal fluency (mean $\pm$ SD)                       | 77.305 $\pm$ 14.45    | 86.047 $\pm$ 16.356   | –1.980, 0.053                          |
| Emotional intelligence variables                     |                       |                       |                                        |
| MSCEIT EIQ (mean $\pm$ SD)                           | 120.09 $\pm$ 13.918   | 107.46 $\pm$ 17.363   | 2.733, <b>0.009</b>                    |
| MSCEIT Experiential - CIEEX (mean $\pm$ SD)          | 113.74 $\pm$ 12.832   | 101.65 $\pm$ 14.819   | 2.957, <b>0.005</b>                    |
| MSCEIT Strategic - CIES (mean $\pm$ SD)              | 106.43 $\pm$ 12.116   | 101.57 $\pm$ 15.337   | 1.193, 0.240                           |
| MSCEIT Perceiving emotions - CIEP (mean $\pm$ SD)    | 113.61 $\pm$ 13.079   | 101.25 $\pm$ 15.264   | 2.985, <b>0.005</b>                    |
| MSCEIT Facilitating Emotions - CIEF (mean $\pm$ SD)  | 108.77 $\pm$ 12.216   | 100.74 $\pm$ 13.525   | 2.093, <b>0.042</b>                    |
| MSCEIT Understanding emotions - CIEC (mean $\pm$ SD) | 104.22 $\pm$ 13.253   | 101.83 $\pm$ 12.253   | 0.633, 0.530                           |
| MSCEIT Managing emotions - CIEM (mean $\pm$ SD)      | 101.96 $\pm$ 22.542   | 100.71 $\pm$ 17.026   | 0.214, 0.832                           |

Abbreviations: EIQ = Emotional Intelligence Quotient; FAST = Functional Assessment Staging; FEM = First Episode Mania; F=Females; M = Males; MADRS = Montgomery-Asberg Depression Rating Scale; MSCEIT = Mayer-Salovey-Caruso Emotional Intelligence Test; PANSS=Positive and Negative Syndrome Scale; PAS=Premorbid Adjustment Scale; SD=Standard Deviation; YMRS=Young Mania Rating Scale. Bold for statistically significant *p* values.

## 2.8. Statistical analysis

Descriptive statistics were used to define sample characteristics. Continuous variables were given as mean value  $\pm$  SD and were compared using Student *t*-test. Categorical variables were expressed as total number and percentages and differences among groups were assessed through Chi-square ( $\chi^2$ ) or Fisher's exact test as appropriate.

Principal Component Analysis (PCA) was used for neuropsychological variables, to reduce measures to a few principal domains and avoid repetitive information of separate test cognitive variables (for example, semantic cued recall (Short and Long Delay) of CVLT and free recall). The neuropsychological assessment was represented by five factor scores (verbal memory, logical memory, executive functions, sustained attention, and verbal fluency) (Supporting Table 1).

First, clinical and neuropsychological variables were compared between sexes (males and females) and diagnostic groups (FEM and FEP). Next, performance on clinical and socio-demographic, neuropsychological variables and psychosocial functioning was also compared between diagnostic groups through general linear models (GLM), with sex

and group as main effects and the group by sex interactions. In case of significant interactions between sex and group, post-hoc Bonferroni pairwise comparisons were applied. In all GLM, Estimated Marginal Means or adjusted prevalence and the 95 % Interval of confidence (IC) were reported for each variable of interest. All analyses were performed with the IBM Statistical Package for Social Sciences version 23. Statistical significance was set at *p* < 0.05.

## 3. Results

The total sample consisted of 113 subjects with a mean age of 27.1 years (*SD* = 6.58, range 18–43). The sample included 72 (66.7 %) patients with a FEM (females: 33, 45.83 %), and 41 (36.28 %) patients with a FEP (females: 19, 46.34 %). No differences between diagnostic groups were identified in socio-demographic variables.

### 3.1. Sex differences in FEM

Differences were found in cannabis and alcohol use during the

**Table 2**  
Sex differences in FEP

| Prodromal phase                                      | Groups               |                      | Statistics              |
|------------------------------------------------------|----------------------|----------------------|-------------------------|
|                                                      | F-FEP(n = 19)        | M-FEP(n = 22)        | t or $\chi^2$ , p-value |
| Alcohol use (n, %)                                   |                      |                      | 7.553,                  |
| No                                                   | 10, 52.6             | 11, 50               | <b>0.035</b>            |
| <1 unit/week                                         | 1, 5.3               | 0                    |                         |
| 1–5 units/week                                       | 8, 42.1              | 5, 22.7              |                         |
| >5 units/week                                        | 0                    | 6, 27.3              |                         |
| Cannabis use (n, %)                                  |                      |                      | 0.46,                   |
| No                                                   | 10, 52.6             | 13, 59.09            | 1                       |
| <1 cig/week                                          | 1, 5.3               | 1, 4.55              |                         |
| 1–5 cig/week                                         | 4, 21.1              | 4, 18.18             |                         |
| >5 cig/sem                                           | 4, 21.1              | 4, 18.18             |                         |
| Prodromal symptoms                                   |                      |                      |                         |
| Communication difficulty, yes (n, %)                 | 1, 5.3               | 7, 31.8              | 5.115, <b>0.05</b>      |
| Clinical variables                                   |                      |                      |                         |
| MADRS (mean $\pm$ SD)                                | 9.50 $\pm$ 8.009     | 8.86 $\pm$ 6.374     | 0.274, 0.786            |
| YMRS (mean $\pm$ SD)                                 | 1.33 $\pm$ 2         | 1.90 $\pm$ 2.300     | 0.830, 0.412            |
| PANSS Total Score (mean $\pm$ SD)                    | 52.50 $\pm$ 11.346   | 52.86 $\pm$ 20.043   | 0.417, 0.679            |
| PANSS positive symptoms (mean $\pm$ SD)              | 10.33 $\pm$ 4.665    | 10.05 $\pm$ 4.260    | 0.198, 0.844            |
| PANSS negative symptoms (mean $\pm$ SD)              | 14.11 $\pm$ 4.351    | 15.81 $\pm$ 8.524    | 0.763, 0.450            |
| PANSS general psychopathology (mean $\pm$ SD)        | 28.06 $\pm$ 5.589    | 27 $\pm$ 9.386       | 0.417, 0.679            |
| FAST Total Score (mean $\pm$ SD)                     | 23.00 $\pm$ 8.725    | 27.64 $\pm$ 14.114   | 1.272, 0.212            |
| FAST autonomy (mean $\pm$ SD)                        | 2.67 $\pm$ 2         | 4.38 $\pm$ 2.872     | 2.186, <b>0.04</b>      |
| FAST working functioning (mean $\pm$ SD)             | 8.61 $\pm$ 4.960     | 9.09 $\pm$ 5.631     | 0.286, 0.776            |
| FAST cognitive functioning (mean $\pm$ SD)           | 4.50 $\pm$ 2.595     | 5.91 $\pm$ 4.034     | 1.335, 0.190            |
| FAST finances (mean $\pm$ SD)                        | 1.11 $\pm$ 1.568     | 0.64 $\pm$ 1.049     | 1.099, 0.281            |
| FAST relationships (mean $\pm$ SD)                   | 3.78 $\pm$ 3.209     | 5.77 $\pm$ 3.491     | 1.880, 0.068            |
| FAST leisure (mean $\pm$ SD)                         | 2.33 $\pm$ 2.029     | 2.05 $\pm$ 1.588     | 0.491, 0.627            |
| PAS (mean $\pm$ SD)                                  | 14.94 $\pm$ 8.781    | 16.90 $\pm$ 9.049    | 0.685, 0.498            |
| Neuropsychological variables                         |                      |                      |                         |
| Intellectual quotient (mean $\pm$ SD)                | 100.63 $\pm$ 13.769  | 102.05 $\pm$ 12.250  | −0.321, 0.750           |
| Working memory (mean $\pm$ SD)                       | 85.08 $\pm$ 10.452   | 88.29 $\pm$ 16.885   | −0.641, 0.527           |
| Processing speed (mean $\pm$ SD)                     | 97.67 $\pm$ 11.331   | 85.95 $\pm$ 14.939   | 2.601, <b>0.014</b>     |
| Verbal memory (mean $\pm$ SD)                        | 224.632 $\pm$ 39.975 | 175.584 $\pm$ 57.593 | 2.961, <b>0.006</b>     |
| Logical memory (mean $\pm$ SD)                       | 188.091 $\pm$ 44.78  | 178.905 $\pm$ 41.921 | 0.579, 0.568            |
| Executive function (mean $\pm$ SD)                   | 143.483 $\pm$ 9.379  | 134.393 $\pm$ 20.287 | 1.684, 0.105            |
| Sustained attention (mean $\pm$ SD)                  | 134.66 $\pm$ 16.544  | 137.935 $\pm$ 16.02  | −0.581, 0.566           |
| Visual memory (mean $\pm$ SD)                        | 55.64 $\pm$ 6.812    | 54.42 $\pm$ 7.191    | 0.493, 0.526            |
| Verbal fluency (mean $\pm$ SD)                       | 78.573 $\pm$ 10.268  | 67.762 $\pm$ 16.412  | 2.328, <b>0.027</b>     |
| Emotional intelligence variables                     |                      |                      |                         |
| MSCEIT EIQ (mean $\pm$ SD)                           | 119.10 $\pm$ 17.032  | 101.67 $\pm$ 18.112  | 2.322, <b>0.031</b>     |
| MSCEIT Experiential - CIEQ (mean $\pm$ SD)           | 108.8 $\pm$ 13.045   | 95 $\pm$ 14.715      | 2.331, <b>0.03</b>      |
| MSCEIT Strategic - CIES (mean $\pm$ SD)              | 104.40 $\pm$ 11.207  | 97.42 $\pm$ 11.912   | 1.414, 0.173            |
| MSCEIT Perceiving emotions - CIEP (mean $\pm$ SD)    | 106.00 $\pm$ 14.119  | 96.58 $\pm$ 13.166   | 1.606, 0.125            |
| MSCEIT Facilitating Emotions - CIEF (mean $\pm$ SD)  | 111.5 $\pm$ 15.707   | 96.91 $\pm$ 13.166   | 2.122, <b>0.047</b>     |
| MSCEIT Understanding emotions - CIEC (mean $\pm$ SD) | 101.70 $\pm$ 11.186  | 103.27 $\pm$ 12.571  | 0.303, 0.765            |
| MSCEIT Managing emotions - CIEM (mean $\pm$ SD)      | 105.20 $\pm$ 11.094  | 93.33 $\pm$ 13.819   | 2.234, <b>0.037</b>     |

Abbreviations: EIQ = Emotional Intelligence Quotient; FAST = Functional Assessment Staging; FEP=First Episode Psychosis; F=Females; M = Males; MADRS = Montgomery-Asberg Depression Rating Scale; MSCEIT = Mayer-Salovey-Caruso Emotional Intelligence Test; PANSS=Positive and Negative Syndrome Scale; PAS=Premorbid Adjustment Scale; SD=Standard Deviation; YMRS=Young Mania Rating Scale. Bold for statistically significant p values.

prodromal phase (Table 1).

The prodrome *Concentration Difficulties* was predominant among males ( $p = 0.046$ ). However, *Irritability* was more frequent among females ( $p = 0.016$ ).

No differences were found as for clinical variables (Table 1). Significantly higher IQ scores were found in FEM males in comparison with females ( $p = 0.016$ ) and performed better at working memory evaluation ( $p < 0.001$ ).

FEM females obtained better results than males at EIQ ( $p = 0.009$ ), in the Experiential Area (CIEQ;  $p = 0.005$ ) and in the specific EIQ branches: Perceiving emotion (CIEP;  $p = 0.005$ ) and Facilitating Emotions (CIEF;  $p = 0.042$ ).

### 3.2. Sex differences in FEP

During the prodromal phase, there were no significant differences between males and females in the use of cannabis (Table 2). Nevertheless, there were significant differences in alcohol use ( $p = 0.035$ ).

As for prodromal symptoms, *Communication difficulties* were

predominant among males ( $p = 0.05$ ).

No differences were reported in terms of clinical variables (Table 2). The two groups differed in the autonomy FAST subdomain, with worse autonomy for males ( $p = 0.04$ ).

FEP females attained higher scores than FEP males at processing speed estimation ( $p = 0.014$ ), performed better at verbal memory evaluation ( $p = 0.006$ ) and verbal fluency assessment ( $p = 0.027$ ).

Females obtained better results in EIQ than males ( $p = 0.031$ ), showing differences in the Experiential area (CIEQ;  $p = 0.03$ ) and in the Facilitating Emotions (CIEF;  $p = 0.047$ ) and Managing emotions (CIEM;  $p = 0.037$ ) branches.

### 3.3. Differences in FEM and FEP females

No difference was reported in cannabis and alcohol use (Table 3).

The prodromes *Speech pressure* ( $p = 0.014$ ), *Sleep decrease* ( $p = 0.004$ ), *Increased creativity* ( $p = 0.06$ ) and *Lability* ( $p = 0.007$ ) were significantly more common in FEM females. On the contrary, *Decreased energy* ( $p = 0.014$ ) was more frequent in the group of FEP females.



**Table 3**  
Differences in females with a FEM or a FEP.

| Prodromal phase                                      | Groups               |                      | Statistics              |
|------------------------------------------------------|----------------------|----------------------|-------------------------|
|                                                      | F-FEM(n = 33)        | F-FEP(n = 19)        | t or $\chi^2$ , p-value |
| Alcohol use (n, %)                                   |                      |                      | 2.509,                  |
| No                                                   | 15, 48.4             | 10, 52.6             | 0.509                   |
| <1 unit/week                                         | 5, 16.1              | 1, 5.3               |                         |
| 1–5 units/week                                       | 9, 29                | 8, 42.1              |                         |
| >5 units/week                                        | 2, 6.5               | 0                    |                         |
| Cannabis use (n, %)                                  |                      |                      | 1.904,                  |
| No                                                   | 17, 53.1             | 10, 52.6             | 0.68                    |
| <1                                                   | 0                    | 1, 5.3               |                         |
| cig/week                                             | 9, 28.1              | 4, 21.1              |                         |
| 1–5 cig/week                                         | 6, 18.8              | 4, 21.1              |                         |
| >5 cig/sem                                           |                      |                      |                         |
| Prodromal symptoms                                   |                      |                      |                         |
| Decreased energy, yes (n, %)                         | 0                    | 4, 21.1              | 8.647, <b>0.014</b>     |
| Lability, yes (n, %)                                 | 16, 48.5             | 2, 10.5              | 8.579, <b>0.007</b>     |
| Speech pressure, yes (n, %)                          | 7, 21.2              | 0                    | 6.981, <b>0.029</b>     |
| Sleep decrease, yes (n, %)                           | 11, 33.3             | 0                    | 11.653, <b>0.004</b>    |
| Increased creativity, yes (n, %)                     | 10, 30.3             | 0                    | 10.428, <b>0.006</b>    |
| Clinical variables                                   |                      |                      |                         |
| MADRS (mean $\pm$ SD)                                | 6.28 $\pm$ 6.065     | 9.50 $\pm$ 8.009     | –1.483, 0.149           |
| YMRS (mean $\pm$ SD)                                 | 1.39 $\pm$ 1.694     | 1.33 $\pm$ 2.000     | 0.109, 0.914            |
| PANSS Total Score (mean $\pm$ SD)                    | 40.55 $\pm$ 9.504    | 52.50 $\pm$ 11.346   | –3.802, <b>0.001</b>    |
| PANSS positive symptoms (mean $\pm$ SD)              | 7.48 $\pm$ 1.121     | 10.33 $\pm$ 4.665    | –2.551, <b>0.020</b>    |
| PANSS negative symptoms (mean $\pm$ SD)              | 10.39 $\pm$ 4.387    | 14.11 $\pm$ 4.351    | –2.907, <b>0.006</b>    |
| PANSS general psychopathology (mean $\pm$ SD)        | 22.67 $\pm$ 6.06     | 28.06 $\pm$ 5.589    | –3.193, <b>0.003</b>    |
| FAST Total Score (mean $\pm$ SD)                     | 15.36 $\pm$ 11.48    | 23 $\pm$ 8.725       | –2.663, <b>0.011</b>    |
| FAST autonomy (mean $\pm$ SD)                        | 1.82 $\pm$ 2.007     | 2.67 $\pm$ 2.000     | –1.446, 0.157           |
| FAST working functioning (mean $\pm$ SD)             | 5.64 $\pm$ 5.6       | 8.61 $\pm$ 4.960     | –1.954, 0.058           |
| FAST cognitive functioning (mean $\pm$ SD)           | 2.85 $\pm$ 2.347     | 4.50 $\pm$ 2.595     | –2.245, <b>0.032</b>    |
| FAST finances (mean $\pm$ SD)                        | 0.18 $\pm$ 0.584     | 1.11 $\pm$ 1.568     | –2.425, <b>0.025</b>    |
| FAST relationships (mean $\pm$ SD)                   | 2.82 $\pm$ 3.147     | 3.78 $\pm$ 3.209     | –1.027, 0.311           |
| FAST leisure (mean $\pm$ SD)                         | 2.06 $\pm$ 2.061     | 2.33 $\pm$ 2.029     | –0.456, 0.651           |
| PAS (mean $\pm$ SD)                                  | 11.12 $\pm$ 8.069    | 14.94 $\pm$ 8.781    | –1.528, 0.136           |
| Neuropsychological variables                         |                      |                      |                         |
| Intellectual quotient (mean $\pm$ SD)                | 100.41 $\pm$ 10.762  | 100.63 $\pm$ 13.769  | –0.053, 0.958           |
| Working memory (mean $\pm$ SD)                       | 86.52 $\pm$ 11.956   | 85.08 $\pm$ 10.452   | 0.390, 0.700            |
| Processing speed (mean $\pm$ SD)                     | 99.15 $\pm$ 16.868   | 97.67 $\pm$ 11.331   | 0.736, 1.481            |
| Verbal memory (mean $\pm$ SD)                        | 234.765 $\pm$ 43.559 | 224.632 $\pm$ 39.975 | 0.764, 0.450            |
| Logical memory (mean $\pm$ SD)                       | 209.778 $\pm$ 36.982 | 188.091 $\pm$ 44.780 | 1.492, 0.151            |
| Executive function (mean $\pm$ SD)                   | 134.876 $\pm$ 23.947 | 143.483 $\pm$ 9.379  | –1.617, 0.115           |
| Sustained attention (mean $\pm$ SD)                  | 133.298 $\pm$ 15.661 | 134.66 $\pm$ 16.544  | –0.256, 0.800           |
| Visual Memory (mean $\pm$ SD)                        | 56.95 $\pm$ 12.536   | 55.64 $\pm$ 6.812    | –0.418, 0.679           |
| Verbal fluency (mean $\pm$ SD)                       | 77.305 $\pm$ 14.45   | 78.573 $\pm$ 10.268  | –0.312, 0.757           |
| Emotional intelligence variables                     |                      |                      |                         |
| MSCEIT EIQ (mean $\pm$ SD)                           | 120.09 $\pm$ 13.918  | 119.10 $\pm$ 17.032  | 0.161, 0.874            |
| MSCEIT Experiential - CIEQ (mean $\pm$ SD)           | 113.74 $\pm$ 12.832  | 108.8 $\pm$ 13.045   | 1.005, 0.329            |
| MSCEIT Strategic - CIES (mean $\pm$ SD)              | 106.43 $\pm$ 12.116  | 104.40 $\pm$ 11.207  | 0.468, 0.646            |
| MSCEIT Perceiving emotions - CIEP (mean $\pm$ SD)    | 113.61 $\pm$ 13.079  | 106.00 $\pm$ 14.119  | 1.454, 0.165            |
| MSCEIT Facilitating Emotions - CIEF (mean $\pm$ SD)  | 108.77 $\pm$ 12.216  | 111.5 $\pm$ 15.707   | –0.486, 0.634           |
| MSCEIT Understanding emotions - CIEC (mean $\pm$ SD) | 104.22 $\pm$ 13.253  | 101.70 $\pm$ 11.186  | 0.561, 0.581            |
| MSCEIT Managing emotions - CIEM (mean $\pm$ SD)      | 101.96 $\pm$ 22.542  | 105.20 $\pm$ 11.094  | –0.553, 0.584           |

Abbreviations: EIQ = Emotional Intelligence Quotient; FAST = Functional Assessment Staging; FEM = First Episode Mania; FEP=First Episode Psychosis; F=Females; M = Males; MADRS = Montgomery-Asberg Depression Rating Scale; MSCEIT = Mayer-Salovey-Caruso Emotional Intelligence Test; PANSS=Positive and Negative Syndrome Scale; PAS=Premorbid Adjustment Scale; SD=Standard Deviation; YMRS=Young Mania Rating Scale. Bold for statistically significant p values.

PANSS total scores were significantly higher in FEP females ( $p = 0.001$ ) plus all PANSS subscales punctuations. FEP Females also obtained higher FAST total score and consequently worse psychosocial functioning ( $p = 0.011$ ), particularly in the FAST cognitive functioning ( $p = 0.032$ ) and FAST finances ( $p = 0.025$ ) subdomains.

No differences on neuropsychological variables or EI were observed (Table 3).

### 3.4. Differences in FEM and FEP males

There were no significant differences between males with a FEM or a FEP as for the use of alcohol (Table 4). Nonetheless, there were significant differences as for the use of cannabis ( $p = 0.023$ ).

FEP males reported more frequently than FEM males the prodromal symptoms *Isolation* ( $p = 0.047$ ) and *Depression* ( $p = 0.007$ ). The

prodromal symptoms more frequently reported by FEM males were *Agitation* ( $p = 0.018$ ), *Mood elevation* ( $p = 0.001$ ), *Speech pressure* ( $p = 0.02$ ), *Racing thoughts* ( $p = 0.018$ ), *Increased energy* ( $p < 0.001$ ), *Decreased need for sleep* ( $p = 0.018$ ), *Increased self-esteem* ( $p = 0.002$ ) and *Increase creativity* ( $p = 0.002$ ).

Differences were found for clinical variables: PANSS total score ( $p = 0.006$ ), PANSS positive symptoms ( $p = 0.042$ ) and PANSS negative symptoms ( $p = 0.003$ ) were higher in FEP than FEM males.

The FAST domains of autonomy and cognitive functioning were significantly worse in the FEP group ( $p = 0.047$  and  $p = 0.021$ , respectively).

Significant differences were reported in several neuropsychological variables with better results in males with a FEM than a FEP in working memory ( $p = 0.021$ ), processing speed ( $p = 0.001$ ), verbal memory ( $p = 0.01$ ) and verbal fluency ( $p = 0.001$ ). FEP males accomplished a better

**Table 4**

Differences in males with a FEM or a FEP.

| Prodromal phase                                      | Groups               |                      | Statistics<br><i>t</i> or $\chi^2$ , <i>p</i> -value |
|------------------------------------------------------|----------------------|----------------------|------------------------------------------------------|
|                                                      | M-FEM(n = 39)        | M-FEP(n = 22)        |                                                      |
| Alcohol use (n, %)                                   |                      |                      | 4.015,                                               |
| No                                                   | 10, 40               | 11, 50               | 0.244                                                |
| <1 unit/week                                         | 3, 8.1               | 0                    |                                                      |
| 1–5 units/week                                       | 13, 35.1             | 5, 22.7              |                                                      |
| >5 units/week                                        | 11, 29.76            | 6, 27.3              |                                                      |
| Cannabis use (n, %)                                  |                      |                      | 9.075,                                               |
| No                                                   | 8, 32                | 13, 59.09            | <b>0.027</b>                                         |
| <1 cig/week                                          | 3, 8.1               | 1, 4.55              |                                                      |
| 1–5 cig/week                                         | 6, 16.2              | 4, 18.18             |                                                      |
| >5 cig/sem                                           | 20, 54.1             | 4, 18.18             |                                                      |
| Prodromal symptoms                                   |                      |                      |                                                      |
| Isolation, yes (n, %)                                | 9, 23.1              | 11, 50               | 4.627, <b>0.047</b>                                  |
| Depression, yes (n, %)                               | 1, 2.6               | 6, 27.3              | 8.453, <b>0.007</b>                                  |
| Agitation, yes (n, %)                                | 16, 41               | 2, 9.1               | 6.896, <b>0.018</b>                                  |
| Mood elevation, yes (n, %)                           | 17, 43.6             | 1, 4.5               | 10.380, <b>0.001</b>                                 |
| Speech pressure, yes (n, %)                          | 16, 41               | 1, 4.5               | 9.312, <b>0.02</b>                                   |
| Racing thoughts, yes (n, %)                          | 15, 38.5             | 2, 9.1               | 6.036, <b>0.018</b>                                  |
| Increased energy, yes (n, %)                         | 22, 56.4             | 1, 4.5               | 16.108, <b>&lt;0.001</b>                             |
| Decreased need for sleep, yes (n, %)                 | 16, 41               | 2, 9.1               | 6.896, <b>0.018</b>                                  |
| Increased self-esteem, yes (n, %)                    | 16, 41               | 1, 4.5               | 9.312, <b>0.002</b>                                  |
| Increased creativity, yes (n, %)                     | 13, 33.3             | 0                    | 9.319, <b>0.002</b>                                  |
| Clinical variables                                   |                      |                      |                                                      |
| MADRS (mean $\pm$ SD)                                | 5.97 $\pm$ 5.325     | 8.86 $\pm$ 6.374     | –1.761, 0.087                                        |
| YMRS (mean $\pm$ SD)                                 | 2.13 $\pm$ 2.931     | 1.90 $\pm$ 2.300     | 0.325, 0.746                                         |
| PANSS Total Score (mean $\pm$ SD)                    | 41.18 $\pm$ 11.461   | 52.86 $\pm$ 20.043   | –2.854, <b>0.006</b>                                 |
| PANSS positive symptoms (mean $\pm$ SD)              | 8.21 $\pm$ 2.549     | 10.05 $\pm$ 4.260    | –2.077, <b>0.042</b>                                 |
| PANSS negative symptoms (mean $\pm$ SD)              | 10.37 $\pm$ 5.17     | 15.81 $\pm$ 8.524    | –3.057, <b>0.003</b>                                 |
| PANSS general psychopathology (mean $\pm$ SD)        | 22.61 $\pm$ 5.833    | 27 $\pm$ 9.386       | –1.948, 0.061                                        |
| FAST Total Score (mean $\pm$ SD)                     | 20.41 $\pm$ 14.649   | 27.64 $\pm$ 14.114   | –1.876, 0.067                                        |
| FAST autonomy (mean $\pm$ SD)                        | 2.72 $\pm$ 3.095     | 4.38 $\pm$ 2.872     | –2.044, <b>0.047</b>                                 |
| FAST working functioning (mean $\pm$ SD)             | 7.95 $\pm$ 6.018     | 9.09 $\pm$ 5.631     | –0.736, 0.465                                        |
| FAST cognitive working (mean $\pm$ SD)               | 3.51 $\pm$ 2.978     | 5.91 $\pm$ 4.034     | –2.420, <b>0.021</b>                                 |
| FAST finances (mean $\pm$ SD)                        | 0.54 $\pm$ 1.282     | 0.64 $\pm$ 1.049     | –0.312, 0.756                                        |
| FAST relationships (mean $\pm$ SD)                   | 3.89 $\pm$ 3.985     | 5.77 $\pm$ 3.491     | –1.897, 0.064                                        |
| FAST leisure (mean $\pm$ SD)                         | 1.86 $\pm$ 1.858     | 2.05 $\pm$ 1.588     | –0.396, 0.694                                        |
| PAS (mean $\pm$ SD)                                  | 12.49 $\pm$ 7.301    | 16.90 $\pm$ 9.049    | –1.925, 0.063                                        |
| Neuropsychological variables                         |                      |                      |                                                      |
| Intellectual quotient (mean $\pm$ SD)                | 108.29 $\pm$ 13.612  | 102.05 $\pm$ 12.250  | 1.675, 0.102                                         |
| Working memory (mean $\pm$ SD)                       | 100.27 $\pm$ 14.786  | 88.29 $\pm$ 16.885   | 2.441, <b>0.021</b>                                  |
| Processing speed (mean $\pm$ SD)                     | 101.71 $\pm$ 16.939  | 85.95 $\pm$ 14.939   | 3.439, <b>0.001</b>                                  |
| Verbal memory (mean $\pm$ SD)                        | 220.272 $\pm$ 53.606 | 175.584 $\pm$ 57.593 | 2.701, <b>0.010</b>                                  |
| Logical memory (mean $\pm$ SD)                       | 205.538 $\pm$ 47.662 | 178.905 $\pm$ 41.921 | 1.929, 0.061                                         |
| Executive function (mean $\pm$ SD)                   | 137.818 $\pm$ 22.345 | 134.393 $\pm$ 20.287 | 0.548, 0.587                                         |
| Sustained attention (mean $\pm$ SD)                  | 127.227 $\pm$ 10.95  | 137.935 $\pm$ 16.02  | –2.537, <b>0.017</b>                                 |
| Visual memory (mean $\pm$ SD)                        | 56.28 $\pm$ 6.654    | 54.42 $\pm$ 7.191    | 0.89, 0.38                                           |
| Verbal fluency (mean $\pm$ SD)                       | 86.047 $\pm$ 16.356  | 67.762 $\pm$ 16.412  | 3.693, <b>0.001</b>                                  |
| Emotional intelligence variables                     |                      |                      |                                                      |
| MSCEIT EIQ (mean $\pm$ SD)                           | 107.46 $\pm$ 17.363  | 101.67 $\pm$ 18.112  | 0.917, 0.369                                         |
| MSCEIT Experiential - CIEQ (mean $\pm$ SD)           | 101.65 $\pm$ 14.819  | 95 $\pm$ 14.715      | 1.266, 0.218                                         |
| MSCEIT Strategic - CIES (mean $\pm$ SD)              | 101.57 $\pm$ 15.337  | 97.42 $\pm$ 11.912   | 0.882, 0.385                                         |
| MSCEIT Perceiving emotions - CIEP (mean $\pm$ SD)    | 101.25 $\pm$ 15.264  | 96.58 $\pm$ 13.166   | 0.950, 0.351                                         |
| MSCEIT Facilitating Emotions - CIEF (mean $\pm$ SD)  | 100.74 $\pm$ 13.525  | 96.91 $\pm$ 13.166   | –0.315, 0.755                                        |
| MSCEIT Understanding emotions - CIEC (mean $\pm$ SD) | 101.83 $\pm$ 12.253  | 103.27 $\pm$ 12.571  | –0.315, 0.756                                        |
| MSCEIT Managing emotions - CIEM (mean $\pm$ SD)      | 100.71 $\pm$ 17.026  | 93.33 $\pm$ 13.819   | 1.394, 0.175                                         |

Abbreviations: EIQ = Emotional Intelligence Quotient; FAST = Functional Assessment Staging; FEM = First Episode Mania; FEP=First Episode Psychosis; F=Females; M = Males; MADRS = Montgomery-Asberg Depression Rating Scale; MSCEIT = Mayer-Salovey-Caruso Emotional Intelligence Test; PANSS=Positive and Negative Syndrome Scale; PAS=Premorbid Adjustment Scale; SD=Standard Deviation; YMRS=Young Mania Rating Scale. Bold for statistically significant *p* values.

perform at sustained attention evaluation ( $p = 0.017$ ). No differences on emotional intelligence scores were observed.

### 3.5. General linear model analysis

There were significant main effects for sex for neuropsychological variables, namely working memory and verbal memory (Table 5). While females performed better in verbal memory ( $\chi^2 = 9.038$ ,  $p = 0.003$ ), males obtained better results in working memory ( $\chi^2 = 7.627$ ,  $p = 0.006$ ). Furthermore, main effects for sex were reported for the MSCEIT task. In particular, females obtained a higher EIQ ( $\chi^2 = 13.20$ ,  $p < 0.001$ ) and performed better than males in the Experiential Area ( $\chi^2 = 13.63$ ,  $p$

$< 0.001$ ), and in the MSCEIT branches Perceiving emotions ( $\chi^2 = 9.504$ ,  $p < 0.001$ ) and Facilitating emotions ( $\chi^2 = 10.17$ ,  $p < 0.001$ ).

There were significant main effects for group for most of the clinical features. Higher MADRS ( $\chi^2 = 6.170$ ,  $p = 0.013$ ) and PANSS scores (PANSS positive symptoms:  $\chi^2 = 14.912$ ,  $p < 0.001$ ; PANSS negative symptoms:  $\chi^2 = 17.084$ ,  $p < 0.001$ ; PANSS general psychopathology  $\chi^2 = 13.938$ ,  $p < 0.001$ ; and PANSS total scores  $\chi^2 = 21.382$ ,  $p < 0.001$ ) were reported for FEP than FEM patients. In terms of functioning, FEP patients also reported higher FAST scores ( $\chi^2 = 8.815$ ,  $p = 0.003$ ) in comparison with FEM patients, indicating worse psychosocial functioning.

As for neuropsychological performance, there were significant main

**Table 5**  
Main effects and interactions for clinical and neurocognitive variables.

| (mean ± SD)                          | FEM (n = 72)                 |                              | FEP (n = 41)                 |                              | Effect         |                  |                |                  |                |              |
|--------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|----------------|------------------|----------------|------------------|----------------|--------------|
|                                      | Male (n = 39)                | Female (n = 33)              | Male (n = 22)                | Female (n = 19)              | Group          |                  | Sex            |                  | GroupXSex      |              |
|                                      | Mean (IC 95 %)               | Mean (IC 95 %)               | Mean (IC 95 %)               | Mean (IC 95 %)               | X <sup>2</sup> | p                | X <sup>2</sup> | p                | X <sup>2</sup> | p            |
| <b>Socio-demographic variables</b>   |                              |                              |                              |                              |                |                  |                |                  |                |              |
| Age                                  | 27.64<br>(25.60–29.69)       | 26.39<br>(24.17–28.62)       | 26.41<br>(23.69–29.13)       | 28 (25.07–30.93)             | 0.021          | 0.884            | 0.018          | 0.893            | 1.231          | 0.267        |
| <b>Clinical variables</b>            |                              |                              |                              |                              |                |                  |                |                  |                |              |
| MADRS                                | 5.97 (4.03–7.92)             | 6.28 (4.16–8.40)             | 8.86 (6.24–11.48)            | 9.50 (6.67–12.33)            | 6.170          | <b>0.013</b>     | 0.150          | 0.699            | 0.019          | 0.891        |
| YMRS                                 | 2.13 (1.40–2.85)             | 1.39 (0.61–2.18)             | 1.90 (0.92–2.89)             | 1.33 (0.27–2.40)             | 0.095          | 0.758            | 2.009          | 0.156            | 0.031          | 0.860        |
| PANSS positive symptoms              | 8.21 (7.25–9.18)             | 7.48 (6.45–8.52)             | 10.05 (8.75–11.35)           | 10.33 (8.93–11.74)           | 14.912         | <b>&lt;0.001</b> | 0.131          | 0.717            | 0.695          | 0.405        |
| PANSS negative symptoms              | 10.37 (8.61–12.13)           | 10.39 (8.50–12.29)           | 15.81<br>(13.44–18.18)       | 14.11<br>(11.55–16.67)       | 17.084         | <b>&lt;0.001</b> | 0.570          | 0.450            | 0.605          | 0.437        |
| PANSS general psychopathology        | 22.61<br>(20.52–24.69)       | 22.67<br>(20.43–24.90)       | 27 (24.20–29.80)             | 28.06<br>(25.03–31.08)       | 13.938         | <b>&lt;0.001</b> | 0.182          | 0.670            | 0.144          | 0.704        |
| PANSS total                          | 41.18<br>(37.12–45.25)       | 40.55<br>(36.18–44.91)       | 52.86<br>(47.39–58.32)       | 52.50<br>(46.59–58.41)       | 21.382         | <b>&lt;0.001</b> | 0.038          | 0.845            | 0.003          | 0.956        |
| FAST total                           | 20.41<br>(16.35–24.46)       | 15.36<br>(11.07–19.66)       | 27.64<br>(22.38–32.89)       | 23 (17.19–28.81)<br>14.94    | 8.815          | <b>0.003</b>     | 3.735          | 0.053            | 0.007          | 0.935        |
| PAS total                            | 12.49 (9.98–14.99)           | 11.12 (8.40–13.84)           | (13.49–20.32)                | (11.36–18.63)                | 6.712          | <b>0.010</b>     | 1.094          | 0.296            | 0.035          | 0.852        |
| <b>Neuropsychological variables</b>  |                              |                              |                              |                              |                |                  |                |                  |                |              |
| Intellectual quotient                | 108.29<br>(103.96–112.62)    | 100.41<br>(95.94–104.89)     | 102.05<br>(96.53–107.58)     | 100.63<br>(94.60–106.65)     | 1.322          | 0.250            | 3.152          | 0.076            | 1.514          | 0.218        |
| Working memory                       | 100.27<br>(95.42–105.11)     | 86.52<br>(81.41–91.62)       | 88.29<br>(81.86–94.73)       | 85.08<br>(77.72–92.43)       | 4.768          | <b>0.029</b>     | 7.627          | <b>0.006</b>     | 2.939          | 0.086        |
| Processing speed                     | 101.71<br>(96.29–107.13)     | 99.15<br>(93.34–104.96)      | 85.95<br>(79.02–92.87)       | 97.67<br>(89.87–105.46)      | 6.648          | <b>0.010</b>     | 1.875          | 0.171            | 4.559          | <b>0.033</b> |
| Verbal memory                        | 220.272<br>(202.606–237.937) | 234.765<br>(215.738–253.791) | 175.584<br>(153.759–197.409) | 224.633 (200–85-<br>248.415) | 6.727          | <b>0.009</b>     | 9.038          | <b>0.003</b>     | 2.673          | 0.102        |
| Logical memory                       | 205.383<br>(188.989–221.776) | 209.779<br>(193.048–226.510) | 178.905<br>(159.585–198.225) | 188.091<br>(165.358–210.825) | 6.194          | <b>0.013</b>     | 0.493          | 0.483            | 0.061          | 0.805        |
| Executive function                   | 137.818<br>(130.597–145.039) | 134.876<br>(126.991–142.761) | 134.394<br>(124.917–143.870) | 143.483<br>(132.738–154.229) | 0.323          | 0.570            | 0.454          | 0.500            | 1.740          | 0.187        |
| Sustained attention                  | 127.277<br>(122.128–132.427) | 133.298<br>(127.638–138.959) | 137.935<br>(131.573–144.297) | 134.66<br>(127.501–141.82)   | 3.693          | 0.055            | 0.193          | 0.661            | 2.209          | 0.137        |
| Visual memory                        | 56.28<br>(53.14–59.43)       | 56.95<br>(53.50–60.41)       | 54.42<br>(50.43–58.41)       | 55.64<br>(51.12–60.17)       | 0.667          | 0.414            | 0.238          | 0.626            | 0.020          | 0.887        |
| Verbal fluency                       | 86.05<br>(80.56–91.53)       | 77.30<br>(71.38–83.23)       | 67.76<br>(60.92–74.61)       | 78.57<br>(71.31–85.83)       | 6.752          | <b>0.009</b>     | 0.100          | 0.752            | 8.913          | <b>0.003</b> |
| <b>Social cognition variables</b>    |                              |                              |                              |                              |                |                  |                |                  |                |              |
| MSCEIT EIQ                           | 107.46<br>(101.09–113.83)    | 120.09<br>(113.44–126.74)    | 101.67<br>(92.66–110.67)     | 119.10<br>(109.24–128.96)    | 0.672          | 0.412            | 13.20          | <b>&lt;0.001</b> | 0.336          | 0.562        |
| MSCEIT Experiential - CIE            | 101.65<br>(96.14–107.16)     | 113.74<br>(108.23–119.25)    | 95 (87.37–102.63)            | 108.80<br>(100.44–117.16)    | 2.733          | 0.098            | 13.63          | <b>&lt;0.001</b> | 0.060          | 0.807        |
| MSCEIT Strategic - CIES              | 101.57<br>(96.34–106.79)     | 106.43<br>(101.21–111.66)    | 97.42<br>(90.18–104.65)      | 104.40<br>(76.47–112.33)     | 0.865          | 0.352            | 3.178          | 0.075            | 0.101          | 0.751        |
| MSCEIT Perceiving emotions - CIEP    | 101.25<br>(95.80–106.70)     | 113.61<br>(108.04–119.18)    | 96.58<br>(88.87–104.30)      | 106<br>(97.55–114.45)        | 3.020          | 0.082            | 9.504          | <b>&lt;0.001</b> | 0.173          | 0.677        |
| MSCEIT Facilitating Emotions - CIEF  | 100.74<br>(95.26–106.22)     | 108.77<br>(103.17–114.38)    | 96.91<br>(88.98–104.83)      | 11.5 (103.19–119-<br>81)     | 0.024          | 0.876            | 10.17          | <b>&lt;0.001</b> | 0.855          | 0.355        |
| MSCEIT Understanding emotions - CIEC | 101.83<br>(96.94–106.73)     | 104.22<br>(99.22–109.22)     | 103.27<br>(96.04–110.51)     | 101.70<br>(94.11–109.29)     | 0.028          | 0.867            | 0.016          | 0.900            | 0.379          | 0.538        |
| MSCEIT Managing emotions - CIEM      | 100.71<br>(93.72–107.70)     | 101.96<br>(94.82–109.10)     | 93.33<br>(83.45–103.22)      | 105.20<br>(94.37–116.03)     | 0.208          | 0.648            | 2.100          | 0.147            | 1.376          | 0.241        |


Abbreviations: EIQ = Emotional Intelligence Quotient; FAST = Functional Assessment Staging; FEM = First Episode Mania; FEP=First Episode Psychosis; IC = Lower–Upper values within Wald Confidence Interval of 95 %; MADRS = Montgomery-Asberg Depression Rating Scale; MSCEIT = Mayer-Salovey-Caruso Emotional Intelligence Test; PANSS=Positive and Negative Syndrome Scale; PAS=Premorbid Adjustment Scale; SD=Standard Deviation; YMRS=Young Mania Rating Scale. Bold for statistically significant p values.

effects for group for working memory ( $\chi^2 = 4.768, p = 0.029$ ), processing speed ( $\chi^2 = 6.648, p = 0.010$ ), verbal memory ( $\chi^2 = 6.727, p = 0.009$ ), logical memory ( $\chi^2 = 6.194, p = 0.013$ ) and verbal fluency ( $\chi^2 = 6.752, p = 0.009$ ), with lower scores for FEP patients than FEM ones. Also, premorbid adjustment was significantly poorer for FEP than FEM patients ( $\chi^2 = 6.712, p = 0.010$ ).

In addition, there were significant group by sex interactions for few neuropsychological variables, namely processing speed ( $\chi^2 = 4.559, p = 0.033$ ) and verbal fluency ( $\chi^2 = 8.913, p = 0.003$ ). Post-hoc Bonferroni

revealed that FEP males performed worse than FEM males in processing speed (Mean Difference-MD = 15.76, Confidence Interval-CI = 3.92–27.60,  $p = 0.003$ ). Similarly, FEP males performed worse than FEM males (MD = 18.28, CI = 30.09–6.48,  $p < 0.001$ ) in verbal fluency (see Fig. 1). Moreover, FEM females performed better than FEP males patients in processing speed (MD = 13.20, 95 % CI = -11.60–14.57,  $p = 0.025$ ).





**Fig. 1.** Significant group by sex interaction in neuropsychological variables. Abbreviations: FEM = First Episode Mania; FEP=First Episode Psychosis.

#### 4. Discussion

The present study explored the differences between females and males in prodromal symptoms, clinical variables, functioning and neuropsychological characteristics of individuals with a FEM or a FEP. The main finding emerging from our analyses is the presence of significant sex effect and group by sex interaction on specific neurocognitive cognition and emotional intelligence measures.

Females performed better than males in verbal memory and obtained a higher EIQ and higher scores in specific EI branches (i.e. Perceiving emotions and Facilitating emotions). Conversely, males obtained better results in working memory. In a study assessing whether male FEP patients have greater neurocognitive impairment than females at illness onset, FEP females outperformed males on verbal memory whilst males presented a better cognitive performance on reaction time, visual memory, and a planning task (Ayesa-Arriola et al., 2014). In a previous study comparing sex differences in neurocognition in BD patients, males also obtained better results than females in working memory (Solé et al., 2022). In the present study, these differences seem to be already present at the early stages of the disease, in FEM or FEP taken together.

As for EI, females outperformed males in EIQ and Perceiving emotions and Facilitating emotions branches. In the general population, a female advantage in the recognition of other people's emotions and in the ability to understand others' feelings has been identified (Di Tella et al., 2020). Regarding EI as a construct, most studies find that women perform better than men (Brackett et al., 2004; Day and Carroll, 2004; Fischer et al., 2018; Joseph and Newman, 2010), while one study found no differences (Pardeller et al., 2017). Regarding psychiatric populations, the results are not conclusive in early episodes of non-affective psychosis: while Labad et al. (Labad et al., 2016) found significant differences between the sexes, Casado Ortega (Casado-Ortega et al., 2021) did not. However, it is worth noting that both studies focused only on the Managing emotions' branch. In chronic stages, the results seem to be more conclusive, and in SCZ patients, females showed better results than males (DeTore et al., 2018; Eack et al., 2010; Ferrer-Quintero et al., 2021). As for BD, differences have been found both at early (Varo et al., 2022) and chronic (Varo et al., 2020) stages, with females outperforming males.

As expected, significant group effect was obtained for most of the clinical features, and FEP patients presented higher depressive and psychotic symptoms as well as worse psychosocial functioning and premorbid adjustment. Group effect was also reported for

neuropsychological variables, particularly in processing speed, working memory, verbal memory, logical memory, and verbal fluency, with lower scores for FEP patients than FEM ones. In a meta-analysis assessing neurocognitive impairment in FEM patients in comparison with FEP and HCs, Bora and Pantelis (Bora and Pantelis, 2015) identified that FEP patients significantly underperformed FEM patients in most cognitive domains, namely processing speed, working memory, verbal memory, and fluency, and on individual tasks, particularly in digit symbol and category fluency. Despite this, the authors identified that the deficits were significant but moderate. They concluded that cognitive differences between FEP and FEM might be quantitative rather than qualitative (Bora and Pantelis, 2015). Even though neuropsychological impairment was already evident in FEM patients, cognitive performance in FEM patients lied in a continuum of cognitive impairment, between FEP patients and HCs (Bora and Pantelis, 2015). Predictors of BD versus SCZ diagnosis were evaluated in a previous longitudinal multicentric study and patients with a final diagnosis of BD had a better baseline premorbid adjustment and psychosocial functioning, lesser negative symptoms and lower number of perseverative errors on the WCST (Monchi et al., 2001), a neuropsychological test assessing the ability to display flexibility in the face of changing schedules of reinforcement (Salagre et al., 2020). Another study found that FEM patients performed better in verbal memory, reasoning and flexibility compared to FEP (Montalvo et al., 2018).

Interestingly, a significant group by sex interaction was found for few neuropsychological variables in the present study. Not only FEM males outperformed FEP males patients in processing speed and verbal fluency but also FEM females performed better than FEP males in processing speed. In the present study, we identified that the processing speed performance not only depended on being a FEP or a FEM patient, but also on the effect exerted by sex. Sex showed an effect on the performance, resulting in FEM females outperforming FEP males. Previous findings on the sex effect on processing speed performance are conflicting. While few studies (Kestens et al., 2021) did not found a clear sex effect, other studies identified that females outperformed males in processing speed (Roivainen et al., 2021). Biological factors have been studied to explain this effect. In particular, hyperprolactinaemia was found to have a negative impact on cognitive function in people with early psychosis (Montalvo et al., 2014). In particular, increased prolactin levels were associated with impaired processing speed in males but not in females, and this association was independent of cortisol and testosterone (Montalvo et al., 2018).

Classically, the prevalence of drug use is higher in males than females (McHugh et al., 2018). The consumption of cannabis is more common among males than in females in all age groups (McHugh et al., 2018). We observed that there was a significant difference in the use of alcohol and cannabis among females and males with a FEM in the prodromal phase. These findings are congruent with the latest report by the Spanish Ministry of Health about alcohol, tobacco and illegal drugs, reporting that in all age groups, alcohol and cannabis consumption is higher among men (Ministerio de Sanidad. Delegación del Gobierno para el Plan Nacional sobre Drogas, 2022). However, the prevalence of cannabis use in our sample is much higher than in general population. Since the use of cannabis and other drugs in adolescents and young adults can lead to early onset FEM or FEP and is associated with comorbidities and worse clinical outcomes (Kahn et al., 2015; Vieta et al., 2018), these findings might have implications for including substance use targeted interventions in current early treatment programs.

In terms of prodromal symptoms, there is growing interest in identifying early manifestations. As for sex differences in mania prodromal symptoms, *Irritability* was more frequently reported in females patients whilst *Concentration difficulties* in males. Psychosis prodromal symptoms were similar in both sexes, despite *Communication difficulties* was more frequently included in the males FEP prodrome. In the comparison of prodromal symptoms in females with a FEM or a FEP, *Decreased energy* was more prevalent in FEP females while *Lability*, *Speech pressure*, *Sleep decrease* and *Increased creativity* in FEM females. In contrast, *Social isolation* and *Depression*, were the specific prodromal symptoms in FEP males whereas *Physical agitation*, *Mood elevation*, *Speech pressure*, *Racing thoughts*, *Increased energy*, *Decreased need for sleep*, *Increased self-esteem* and *Increased creativity* in FEM males. Although *Social isolation* is considered in literature as one of the most prevalent prodromal symptoms of a FEP (Cornblatt et al., 2003; Jackson et al., 1995; Mäki et al., 2014) and an essential component of the initial prodrome in SCZ (Häfner et al., 1999), it only revealed as a noteworthy prodromal symptom of a FEP in the comparison with a FEM in males but not in females. A similar trend was seen for the specific prodromal symptoms of a FEM, such as *Physical agitation* and *Increased energy* (Correll et al., 2007), among others. Therefore, exploring sex differences in prodromal characteristics would make the diagnostic process easier, earlier, and more accurate.

#### 4.1. Limitations

The present study has several limitations. First, we assessed differences between sexes, but we did not assess the influence that gender might exert (Tannenbaum et al., 2016). Second, the retrospective assessment of the prodromes and substance use with possible recall bias should be acknowledged. Third, prodromal symptoms were assessed with the BPSS-R scale, which was not developed to evaluate prodromal symptoms in SCZ (Correll et al., 2007). Nonetheless, the development of the BPSS-R was also based on interviews for the assessment of the psychotic and SCZ prodrome. The BPSS-R was used to assess both FEM and FEP patients to limit this bias. Fourth, the overall sample size is limited, especially for psychosis, with <30 participants between the two sex groups. Indeed, the group of FEP patients was smaller, which might have influenced the valuation of differences between groups. While sample size may be an issue for certain variables (De Prisco and Vieta, 2024), the study power was able to prove the presence of significant sex effect and group by sex interaction on specific neurocognitive cognition and emotional intelligence measures. In addition, the multiple comparisons conducted in our analyses may represent another limitation, raising the concerns for chance findings due to type I errors. However, as the outcomes of our analyses are inter-correlated, it may be not appropriate to adjust *p*-values for multiple comparisons (Barnett et al., 2022). Nonetheless, the present study should be considered as exploratory due to the limitations in sample size, particularly within the psychosis group, and thus the findings should be interpreted with caution. To strengthen the validity and generalizability of the results, replication in future studies,

with larger sample sizes, is essential. Fifth, patients have been included in the study if they experienced their FEP/FEM along the previous four years. Thus, we recruited patients in the early stages of the disease. Sixth, differences in medication might account for some of the differences between males and females and between FEM and FEP (Ilzarbe and Vieta, 2023; Vidal et al., 2023). Finally, we did not count with of a HC group that would allow a comparison with general population.

Despite these limitations, the present study assessed sex differences in FEP and FEM patients, whose comparison was not reported in previous literature. Furthermore, we can rely on clinical, cognitive, and psychosocial outcomes that were assessed using standardized measures.

#### 5. Conclusions

In conclusion, it seems undeniable that sex matters in mental health. The branch of research focused on sex differences should be improved in order to tailor personalised early treatment strategies focused on sex differences. Taking sex into consideration could improve the efficacy of psychological and pharmacological treatments strategies. Indeed, males patients would benefit from treatment strategies aimed at recognizing emotions and accessing feelings. Similarly, neuropsychological-focused improving strategies would consider the variation of cognitive performance between males and females.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jad.2024.10.002>.

#### Author statement

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We understand that Corresponding Authors are the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). They are responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided current, correct email addresses, which are accessible by the Corresponding Authors and have been configured to accept emails from (EVIETA@clinic.cat & AMARTIAR@clinic.cat).

#### Role of the funding sources

The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### Authors' contributions

RPG, NV and SA designed the study, managed the literature searches, undertook the statistical analysis, and wrote the first draft of the manuscript. EV, AMA designed the study and supervised the realization of the study. MSN, MG, MSV, SM, LM, PSP, IM, IP and CGR helped in the recruitment of the patients and in the realization of the study procedures, revised the first draft and added critical comments to guide the redaction of the final manuscript. CT, VSG, EPC, AT, GM, NF and JARQ revised the first draft and added critical comments to guide the redaction of the final manuscript. All the authors revise the second draft of the article and provided critical comments to guide the redaction of the final

manuscript. All authors approved the final manuscript.

### Acknowledgements/financial support

This work was supported by The Secretaria d' Universitats i Recerca del Departament d'Economia i Coneixement (2021 SGR 01128; 2017-SGR-1271); the CIBER -Consorcio Centro de Investigación Biomédica en Red (CIBERSAM), Instituto de Salud Carlos III; the Centres de Recerca de Catalunya-CERCA Programme; the Spanish Ministry of Science, Innovation (CPII16/00018 to EPC, CD20/00177 to SA, PI24/00671 to SA, PI12/0091 to EV, PI15/00283 to EV, PI18/00805 to EV, PI21/00787 to EV, PI24/00432 to EV and AMA, PI18/01001 to IP, PI20/00344 to CT, PI24/00407 to CT) integrated into the Plan Nacional de I + D + I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the “Pla estratègic de Recerca i Innovació en Salut 2016–2020” (SLT006/17/00357 to EV); the La Marató-TV3 Foundation grants 202234–30 (to EV) and 202234–32 (to SA); the Biomedicine international training research programme for excellent clinician-scientists-BITRECS project (Marie-Curie grant No 754550 and “La Caixa” Foundation LCF/PR/GN18/50310006 to NV). SA has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future”. MFF received the support of “*Contratos predoctorales de formación en investigación en salud*” (PFIS22) (FI22/00185) from the *Instituto de Salud Carlos III* (ISCIII). NEF-O thanks the support of the European Union Horizon 2020 research and innovation program (EU.3.1.3. Treating and managing disease: Grant No 945151), and DAAD (*Deutscher Akademischer Austauschdienst*) (ID-57681229 - Ref. No. 91629413).

### CRediT authorship contribution statement

**Roberto Palacios-Garran:** Writing – original draft, Data curation, Conceptualization. **Silvia Amoretti:** Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Maria Serra-Navarro:** Writing – review & editing, Data curation. **Carla Torrent:** Writing – review & editing, Funding acquisition, Data curation. **Marina Garriga:** Writing – review & editing, Data curation. **Natalia E. Fares-Otero:** Writing – review & editing. **Maria Sagué-Vilavella:** Writing – review & editing, Data curation. **Santiago Madero:** Writing – review & editing, Data curation. **M. Florencia Forte:** Writing – review & editing, Data curation. **Laura Montejo:** Writing – review & editing, Data curation. **Pilar Salgado-Pineda:** Writing – review & editing, Data curation. **Irene Montoro:** Writing – review & editing, Data curation. **Vanessa Sánchez-Gistau:** Writing – review & editing, Supervision. **Edith Pomarol-Clotet:** Writing – review & editing, Supervision. **Giulia Menculini:** Writing – review & editing, Supervision. **Alfonso Tortorella:** Writing – review & editing, Supervision. **Isabella Pacchiarotti:** Writing – review & editing, Supervision, Data curation. **Clemente Garcia-Rizo:** Writing – review & editing, Data curation. **Josep Antoni Ramos-Quiroga:** Writing – review & editing, Supervision. **Anabel Martínez-Arán:** Writing – review & editing, Supervision, Conceptualization. **Eduard Vieta:** Writing – review & editing, Conceptualization. **Norma Verdolini:** Writing – review & editing, Writing – original draft, Supervision, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization.

### Declaration of competing interest

RPG has received financial support for CME activities and travel funds the following entities (unrelated to the present work): Angelini, Janssen, Lundbeck, Rovi and Otsuka.

SA has been a consultant to and/or has received honoraria/grants from Otsuka-Lundbeck, with no financial or other relationship relevant

to the subject of this article.

MG has received grants and served as consultant or advisor for Ferrer, Lundbeck, and Janssen-Cilag.

MSV has received financial support for CME activities and travel funds from Janssen-Cilag and Lundbeck, and reports no financial or other relationship relevant to the subject of this article.

JARQ was on the speakers' bureau and/or acted as consultant for Eli-Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice, Rubió and Raffo in the last 5 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogui, Bial, Medice and Eli-Lilly. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 5 years: Eli-Lilly, Lundbeck, Janssen-Cilag, Actelion, Shire, Ferrer, Oryzon, Roche, Psious and Rubió.

VSG has received financial support for CME activities and travel funds the following entities (unrelated to the present work): Angelini, Janssen, Lundbeck, Otsuka.

GM served as speaker/consultant or received travel funds from Angelini, Janssen and Labor Est.

AMA has received funding for research projects and/or honoraria as a consultant or speaker for the following companies and institutions (work unrelated to the topic of this manuscript): Otsuka, Pfizer, Astra-Zeneca, Bristol-Myers Squibb, Lundbeck, the Spanish Ministry of Economy and Competitiveness and Instituto de Salud Carlos III.

IP has received CME-related honoraria or consulting fees from ADAMED, Janssen-Cilag and Lundbeck.

EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, Janssen, Lundbeck, Medincell, Merck, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viartis, outside the submitted work.

NV has received financial support for CME activities and travel funds from the following entities (unrelated to the present work): Angelini, Janssen, Lundbeck, Otsuka.

The rest of authors report no biomedical financial interests or potential conflicts of interest related to the present article.

### Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### References

- Altschuler, L.L., Kupka, R.W., Hellemann, G., Frye, M.A., Sugar, C.A., McElroy, S.L., Nolen, W.A., Grunze, H., Leverich, G.S., Keck, P.E., Zerneno, M., Post, R.M., Suppes, T., 2010. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. *Am. J. Psychiatry* 167, 708–715. <https://doi.org/10.1176/appi.ajp.2009.09010105>.
- American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders. Fifth Edition. ed. Washington DC. <https://doi.org/10.1176/APPI.BOOKS.9780890425596>.
- Ayasa-Arriola, R., Rodríguez-Sánchez, J.M., Gómez-Ruiz, E., Roiz-Santáñez, R., Reeves, L.L., Crespo-Facorro, B., 2014. No sex differences in neuropsychological performance in first episode psychosis patients. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 48, 149–154. <https://doi.org/10.1016/j.pnpb.2013.09.009>.
- Baldassano, C.F., Marangell, L.B., Gyulai, L., Ghaemi, S.N., Joffe, H., Kim, D.R., Sagduyu, K., Truman, C.J., Wisniewski, S.R., Sachs, G.S., Cohen, L.S., 2005. Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. *Bipolar Disord.* 7, 465–470. <https://doi.org/10.1111/j.1399-5618.2005.00237.x>.
- Bangasser, D.A., Valentino, R.J., 2014. Sex differences in stress-related psychiatric disorders: neurobiological perspectives. *Front. Neuroendocrinol.* 35, 303–319. <https://doi.org/10.1016/j.yfrne.2014.03.008>.
- Barajas, A., Pelaez, T., González, O., Usall, J., Iniesta, R., Arteaga, M., Jackson, C., Baños, I., Sánchez, B., Dolz, M., Obiols, J.E., Haro, J.M., Ochoa, S., 2017. Predictive capacity of prodromal symptoms in first-episode psychosis of recent onset. *Early Interv. Psychiatry* 13. <https://doi.org/10.1111/eip.12498>.



- Barnett, M.J., Doroudgar, S., Khosravi, V., Ip, E.J., 2022. Multiple comparisons: to compare or not to compare, that is the question. *Res. Soc. Adm. Pharm.* 18, 2331–2334. <https://doi.org/10.1016/J.SAPHARM.2021.07.006>.
- Benton, A.L., 1967. Problems of test construction in the field of aphasia. *Cortex* 3, 32–58. [https://doi.org/10.1016/S0010-9452\(67\)80005-4](https://doi.org/10.1016/S0010-9452(67)80005-4).
- Berg, E.A., 1948. A simple objective technique for measuring flexibility in thinking. *J. Gen. Psychol.* 39, 15–22. <https://doi.org/10.1080/00221309.1948.9918159/ASSET/CMSS/ASSET/6C468455-B715-4379-B32B-51E9A0D6DB47/00221309.1948.9918159.FP.PNG>.
- Bora, E., Pantelis, C., 2015. Meta-analysis of cognitive impairment in First-episode bipolar disorder: comparison with First-episode schizophrenia and healthy controls. *Schizophr. Bull.* 41, 1095–1104. <https://doi.org/10.1093/SCHBUL/SBU198>.
- Bozikas, V.P., Kosmidis, M.H., Peltakis, A., Giannakou, M., Nimatoudis, I., Karavatos, A., Fokas, K., Garyfallos, G., 2010. Sex differences in neuropsychological functioning among schizophrenia patients. *Aust. N. Z. J. Psychiatry* 44, 333–341. <https://doi.org/10.3109/00048670903489833>.
- Brackett, M.A., Mayer, J.D., Warner, R.M., 2004. Emotional intelligence and its relation to everyday behaviour. *Pers Individ Dif* 36, 1387–1402. [https://doi.org/10.1016/S0191-8869\(03\)00236-8](https://doi.org/10.1016/S0191-8869(03)00236-8).
- Bräunig, P., Sarkar, R., Effenberger, S., Schoofs, N., Krüger, S., 2009. Gender differences in psychotic bipolar mania. *Gend. Med.* 6, 356–361. <https://doi.org/10.1016/j.genm.2009.07.004>.
- Brébion, G., Stephan-Otto, C., Ochoa, S., Nieto, L., Contel, M., Usall, J., 2018. Verbal fluency in male and female schizophrenia patients: different patterns of association with processing speed, working memory span, and clinical symptoms. *Neuropsychology* 32, 65–76. <https://doi.org/10.1037/NEU0000394>.
- Cannon-Spoor, H.E., Potkin, S.G., Jed Wyatt, R., 1982. Measurement of premorbid adjustment in chronic schizophrenia. *Schizophr. Bull.* 8, 470–480. <https://doi.org/10.1093/SCHBUL/8.3.470>.
- Carpiniello, B., Pinna, F., Tusconi, M., Zaccacheddu, E., Fatteri, F., 2012. Gender differences in remission and recovery of schizophrenic and schizoaffective patients: preliminary results of a prospective cohort study. *Schizophr Res Treatment* 2012, 1–8. <https://doi.org/10.1155/2012/576369>.
- Casado-Ortega, A., Vila-Badia, R., Butjosa, A., Del Cacho, N., Serra-Arumí, C., Esteban-Sanjusto, M., Diago, M., Muñoz-Samons, D., Pardo, M., 2021. Social cognition and its relationship with sociodemographic, clinical, and psychosocial variables in first-episode psychosis. *Psychiatry Res.* 302. <https://doi.org/10.1016/J.PSYCHRES.2021.114040>.
- Conners, C., 2005. *Conner's Continuous Performance Test II (CPT II) (Version 5)*. media. oipdf.com. Multi Health Systems Inc.
- Conroy, S.K., Francis, M.M., Hulvershorn, L.A., 2018. Identifying and treating the prodromal phases of bipolar disorder and schizophrenia. *Curr. Treat. Options Psychiatry*. <https://doi.org/10.1007/s40501-018-0138-0>.
- Cornblatt, B.A., Lencz, T., Smith, C.W., Correll, C.U., Auther, A.M., Nakayama, E., 2003. The schizophrenia Prodrome revisited: a neurodevelopmental perspective. *Schizophr. Bull.* 29, 633–651. <https://doi.org/10.1093/OXFORDJOURNALS.SCHBUL.A007036>.
- Correll, C.U., Penzner, J.B., Frederickson, A.M., Richter, J.J., Auther, A.M., Smith, C.W., Kane, J.M., Cornblatt, B.A., 2007. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. *Schizophr. Bull.* 33, 703–714. <https://doi.org/10.1093/SCHBUL/SBM028>.
- Correll, C.U., Hauser, M., Penzner, J.B., Auther, A.M., Kafantaris, V., Saito, E., Olvet, D., Carrión, R.E., Birmaher, B., Chang, K.D., Delbello, M.P., Singh, M.K., Pavuluri, M., Cornblatt, B.A., 2014. Type and duration of subsyndromal symptoms in youth with bipolar I disorder prior to their first manic episode. *Bipolar Disord.* 16, 478–492. <https://doi.org/10.1111/BDI.12194>.
- Day, A.L., Carroll, S.A., 2004. Using an ability-based measure of emotional intelligence to predict individual performance, group performance, and group citizenship behaviours. *Pers Individ Dif* 36, 1443–1458. [https://doi.org/10.1016/S0191-8869\(03\)00240-X](https://doi.org/10.1016/S0191-8869(03)00240-X).
- De Prisco, M., Vieta, E., 2024. The never-ending problem: sample size matters. *Eur. Neuropsychopharmacol.* 79, 17–18. <https://doi.org/10.1016/J.EURONEURO.2023.10.002>.
- Delis, D., Kramer, J., Kaplan, E., Ober, B.A., 1993. *California Verbal Learning Test. The Psychological Corporation, APA PsycTests*.
- DeTore, N.R., Mueser, K.T., McGurk, S.R., 2018. What does the managing emotions branch of the MSCEIT add to the MATRICS consensus cognitive battery? *Schizophr. Res.* 197, 414–420. <https://doi.org/10.1016/J.SCHRES.2018.02.018>.
- Di Tella, M., Miti, F., Ardito, R.B., Adenzato, M., 2020. Social cognition and sex: are men and women really different? *Pers Individ Dif* 162, 110045. <https://doi.org/10.1016/J.PAID.2020.110045>.
- Diflorio, A., Jones, I., 2010. Is sex important gender differences in bipolar disorder. *Int. Rev. Psychiatry*. <https://doi.org/10.3109/09540261.2010.514601>.
- Eack, S.M., Greeno, C.G., Pogue-Geile, M.F., Newhill, C.E., Hogarty, G.E., Keshavan, M. S., 2010. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso emotional intelligence test. *Schizophr. Bull.* 36, 370–380. <https://doi.org/10.1093/SCHBUL/SBN091>.
- Ferrer-Quintero, M., Green, M.F., Horan, W.P., Penn, D.L., Kern, R.S., Lee, J., 2021. The effect of sex on social cognition and functioning in schizophrenia. *Npj schizophrenia* 2021 7, 1–8. <https://doi.org/10.1038/s41537-021-00188-7>.
- First, M.B., Gibbon, M., 2004. The structured clinical interview for DSM-IV Axis I disorders (SCID-I), in: *Comprehensive Handbook of Psychological Assessment*, Vol. 2: Personality Assessment. John Wiley & Sons, Inc., Hoboken, NJ, US, pp. 134–143.
- Fischer, A.H., Kret, M.E., Broekens, J., 2018. Gender differences in emotion perception and self-reported emotional intelligence: a test of the emotion sensitivity hypothesis. *PLoS One* 13. <https://doi.org/10.1371/JOURNAL.PONE.0190712>.
- Gogos, A., Ney, L.J., Seymour, N., Van Rheenen, T.E., Felmingham, K.L., 2019. Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: are gonadal hormones the link? *Br. J. Pharmacol.* 176, 4119–4135. <https://doi.org/10.1111/BPH.14584>.
- Goldstein, J.M., Seidman, L.J., Santangelo, S., Knapp, P.H., Tsuang, M.T., 1994. Are schizophrenic men at higher risk for developmental deficits than schizophrenic women? Implications for adult neuropsychological functions. *J. Psychiatr. Res.* 28, 483–498. [https://doi.org/10.1016/0022-3956\(94\)90039-6](https://doi.org/10.1016/0022-3956(94)90039-6).
- Goldstein, J.M., Seidman, L.J., Goodman, J.M., Koren, D., Lee, H., Weintraub, S., Tsuang, M.T., 1998. Are there sex differences in neuropsychological functions among patients with schizophrenia? *Am. J. Psychiatry* 155, 1358–1364. <https://doi.org/10.1176/AJP.155.10.1358>.
- Green, M.F., Bearden, C.E., Cannon, T.D., Fiske, A.P., Helleman, G.S., Horan, W.P., Kee, K., Kern, R.S., Lee, J., Sergi, M.J., Subotnik, K.L., Sugar, C.A., Ventura, J., Yee, C.M., Nuechterlein, K.H., 2012. Social cognition in schizophrenia, part 1: performance across phase of illness. *Schizophr. Bull.* 38, 854–864. <https://doi.org/10.1093/SCHBUL/SBQ171>.
- Häfner, H., Löffler, W., Maurer, K., Hambrecht, M., An Der Heiden, W., 1999. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. *Acta Psychiatr. Scand.* 100, 105–118. <https://doi.org/10.1111/J.1600-0447.1999.TB10831.X>.
- Ilzarbe, L., Vieta, E., 2023. The elephant in the room: medication as confounder. *Eur. Neuropsychopharmacol.* 71, 6–8. <https://doi.org/10.1016/J.EURONEURO.2023.03.001>.
- Jackson, H.J., McGorry, P.D., Dudgeon, P., 1995. Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity. *Compr. Psychiatry* 36, 241–250. [https://doi.org/10.1016/S0010-440X\(95\)90068-3](https://doi.org/10.1016/S0010-440X(95)90068-3).
- Joseph, D.L., Newman, D.A., 2010. Emotional intelligence: An integrative Meta-analysis and cascading model. *J. Appl. Psychol.* 95, 54–78. <https://doi.org/10.1037/A0017286>.
- Kafali, H.Y., Bildik, T., Bora, E., Yuncu, Z., Erermis, H.S., 2019. Distinguishing prodromal stage of bipolar disorder and early onset schizophrenia spectrum disorders during adolescence. *Psychiatry Res.* 275, 315–325. <https://doi.org/10.1016/J.PSYCHRES.2019.03.051>.
- Kahn, R.S., Sommer, I.E., Murray, R.M., Meyer-Lindenberg, A., Weinberger, D.R., Cannon, T.D., O'Donovan, M., Correll, C.U., Kane, J.M., Van Os, J., Insel, T.R., 2015. Schizophrenia. *Nat. Rev. Dis. Primers*. 1. <https://doi.org/10.1038/NRDP.2015.67>.
- Kawa, I., Carter, J.D., Joyce, P.R., Doughty, C.J., Frampton, C.M., Wells, J.E., Walsh, A.E. S., Olds, R.J., 2005. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. *Bipolar Disord.* 7, 119–125. <https://doi.org/10.1111/j.1399-5618.2004.00180.x>.
- Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr. Bull.* 13, 261–276. <https://doi.org/10.1093/schbul/13.2.261>.
- Kestens, K., Degeest, S., Miatton, M., Keppler, H., 2021. Visual and verbal working memory and processing speed across the adult lifespan: the effect of age, sex, educational level, Awakeness, and hearing sensitivity. *Front. Psychol.* 12. <https://doi.org/10.3389/FPSYG.2021.668828>.
- Køster, A., Lajer, M., Lindhardt, A., Rosenbaum, B., 2008. Gender differences in first episode psychosis. *Soc. Psychiatry Psychiatr. Epidemiol.* 43, 940–946. <https://doi.org/10.1007/s00127-008-0384-3>.
- Labad, J., Gutiérrez-Zotes, A., Creus, M., Montalvo, I., Cabezas, Á., Solé, M., Ortega, L., Algora, M.J., Sánchez-Gistau, V., Vilella, E., 2016. Hypothalamic-pituitary-adrenal axis measures and cognitive abilities in early psychosis: are there sex differences? *Psychoneuroendocrinology* 72, 54–62. <https://doi.org/10.1016/J.PSYNEUEN.2016.06.006>.
- Leger, M., Neill, J.C., 2016. A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. *Neurosci. Biobehav. Rev.* 68, 979–1000. <https://doi.org/10.1016/J.NEUBIOREV.2016.06.029>.
- Lewine, R.R.J., Walker, E.F., Shurett, R., Caudle, J., Haden, C., 1996. Sex differences in neuropsychological functioning among schizophrenic patients. *Am. J. Psychiatry* 153, 1178–1184. <https://doi.org/10.1176/AJP.153.9.1178>.
- Mäki, P., Koskela, S., Murray, G.K., Nordström, T., Miettinen, J., Jääskeläinen, E., Veijola, J.M., 2014. Difficulty in making contact with others and social withdrawal as early signs of psychosis in adolescents—the Northern Finland Birth Cohort 1986. *Eur. Psychiatry* 29, 345–351. <https://doi.org/10.1016/J.EURPSY.2013.11.003>.
- Mayer, J.D., Salovey, P., Caruso, D.R., Sitarenios, G., 2003. Measuring emotional intelligence with the MSCEIT V2.0. *Emotion* 3, 97–105. <https://doi.org/10.1037/1528-3542.3.1.97>.
- McHugh, R.K., Votaw, V.R., Sugarman, D.E., Greenfield, S.F., 2018. Sex and gender differences in substance use disorders. *Clin. Psychol. Rev.* 66, 12–23. <https://doi.org/10.1016/J.CPR.2017.10.012>.
- Mendrek, A., Mancini-Marie, A., 2016. Sex/gender differences in the brain and cognition in schizophrenia. *Neurosci. Biobehav. Rev.* 67, 57–78. <https://doi.org/10.1016/J.NEUBIOREV.2015.10.013>.
- Ministerio de Sanidad. Delegación del Gobierno para el Plan Nacional sobre Drogas, 2022. *Observatorio Español de las Drogas y las Adicciones. Informe 2022. Alcohol, tabaco y drogas ilegales en España*. Madrid.
- Monchi, O., Petrides, M., Petre, V., Worsley, K., Dagher, A., 2001. Wisconsin card sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. *J. Neurosci.* 21, 7733–7741. <https://doi.org/10.1523/JNEUROSCI.21-19-07733.2001>.

- Montalvo, I., Gutiérrez-Zotes, A., Creus, M., Monseny, R., Ortega, L., Franch, J., Lawrie, S.M., Reynolds, R.M., Vilella, E., Labad, J., 2014. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. *PLoS One* 9. <https://doi.org/10.1371/JOURNAL.PONE.0089428>.
- Montalvo, I., Nadal, R., Armario, A., Gutiérrez-Zotes, A., Creus, M., Cabezas, Á., Solé, M., Algora, M.J., Sánchez-Gistau, V., Vilella, E., Labad, J., 2018. Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis. *Aust. N. Z. J. Psychiatry* 52, 585–595. <https://doi.org/10.1177/0004867417744254>.
- Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. *Br. J. Psychiatry* 134, 382–389. <https://doi.org/10.1192/bjp.134.4.382>.
- Murray, R.M., Castle, D.J., 1991. The neurodevelopmental basis of sex differences in schizophrenia. *Psychol. Med.* <https://doi.org/10.1017/S0033291700022194>.
- Nivoli, A.M.A., Pacchiarotti, I., Rosa, A.R., Popovic, D., Murru, A., Valenti, M., Bonnin, C. M., Grande, I., Sanchez-Moreno, J., Vieta, E., Colom, F., 2011. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. *J. Affect. Disord.* 133, 443–449. <https://doi.org/10.1016/j.jad.2011.04.055>.
- Ochoa, S., Usall, J., Cobo, J., Labad, X., Kulkarni, J., 2012. Gender differences in schizophrenia and First-episode psychosis: a comprehensive literature review. *Schizophr Res Treatment* 2012, 1–9. <https://doi.org/10.1155/2012/916198>.
- Osterrieth, P.A., 1944. *Le test de copie d'une figure complexe; contribution à l'étude de la perception et de la mémoire*. Arch Psychol (Geneve) 30, 206–356.
- Pardeller, S., Frajo-Apor, B., Kemmler, G., Hofer, A., 2017. Emotional intelligence and cognitive abilities - associations and sex differences. *Psychol. Health Med.* 22, 1001–1010. <https://doi.org/10.1080/13548506.2016.1255766>.
- Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., Lee, J., 2018. Sex: a significant risk factor for neurodevelopmental and neurodegenerative disorders. *Brain Sci.* <https://doi.org/10.3390/brainsci8080154>.
- Pu, C., Qiu, Y., Zhou, T., Yang, F., Lu, Z., Wang, C., Deng, H., Zhao, J., Shi, C., Yu, X., 2019. Gender differences of neurocognitive functioning in patients with first-episode schizophrenia in China. *Compr. Psychiatry* 95. <https://doi.org/10.1016/J.COMPPSYCH.2019.152132>.
- Robb, J.C., Young, L.T., Cooke, R.G., Joffe, R.T., 1998. Gender differences in patients with bipolar disorder influence outcome in the medical outcomes survey (SF-20) subscale scores. *J. Affect. Disord.* 49, 189–193. [https://doi.org/10.1016/S0165-0327\(98\)00003-2](https://doi.org/10.1016/S0165-0327(98)00003-2).
- Roivainen, E., Suokas, F., Saari, A., 2021. An examination of factors that may contribute to gender differences in psychomotor processing speed. *BMC Psychol* 9. <https://doi.org/10.1186/S40359-021-00698-0>.
- Rosa, A.R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J.L., Kapczynski, F., Vieta, E., 2007. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. *Clin. Pract. Epidemiol. Ment. Health* 3, 5. <https://doi.org/10.1186/1745-0179-3-5>.
- Salagre, E., Arango, C., Artigas, F., Ayuso-Mateos, J.L., Bernardo, M., Castro-Fornieles, J., Bobes, J., Desco, M., Fañanás, L., González-Pinto, A., Haro, J.M., Leza, J.C., McKenna, P.J., Meana, J.J., Menchón, J.M., Mico, J.A., Palomo, T., Pazos, A., Pérez, V., Saiz-Ruiz, J., Sanjuán, J., Tabarés-Seisdedos, R., Crespo-Facorro, B., Casas, M., Vilella, E., Palao, D., Olivares, J.M., Rodríguez-Jiménez, R., Vieta, E., 2019. CIBERSAM: ten years of collaborative translational research in mental disorders. *Revista de Psiquiatría y Salud Mental (English Edition)* 12, 1–8. <https://doi.org/10.1016/J.RPSMEN.2018.10.001>.
- Salagre, E., Grande, I., Vieta, E., Mezquida, G., Cuesta, M.J., Moreno, C., Bioque, M., Lobo, A., González-Pinto, A., Moreno, D.M., Corripio, I., Verdolini, N., Castro-Fornieles, J., Mané, A., Pinzon-Espinoza, J., del Mar Bonnin, C., Bernardo, M., 2020. Predictors of bipolar disorder versus schizophrenia diagnosis in a multicenter First psychotic episode cohort: baseline characterization and a 12-month follow-up analysis. *J. Clin. Psychiatry* 81. <https://doi.org/10.4088/JCP.19M12996>.
- Solé, B., Varo, C., Torrent, C., Montejo, L., Jiménez, E., Bonnin, C. del M., Clougher, D., Verdolini, N., Amoretti, S., Piazza, F., Borrás, R., Pomarol-Clotet, E., Sáiz, P.A., García-Portilla, M.P., Vieta, E., Martínez-Arán, A., 2022. Sex differences in neurocognitive and psychosocial functioning in bipolar disorder. *J. Affect. Disord.* 296, 208–215. <https://doi.org/10.1016/J.JAD.2021.09.066>.
- Suominen, K., Mantere, O., Valtonen, H., Arvilommi, P., Leppämäki, S., Isometsä, E., 2009. Gender differences in bipolar disorder type I and II. *Acta Psychiatr. Scand.* 120, 464–473. <https://doi.org/10.1111/j.1600-0447.2009.01407.x>.
- Suppes, T., Mintz, J., McElroy, S.L., Altschuler, L.L., Kupka, R.W., Frye, M.A., Keck, P.E., Nolen, W.A., Leverich, G.S., Grunze, H., Rush, A.J., Post, R.M., 2005. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment network: a sex-specific phenomenon. *Arch. Gen. Psychiatry* 62, 1089–1096. <https://doi.org/10.1001/archpsyc.62.10.1089>.
- Szymanski, S., Lieberman, J.A., Alvir, J.M., Mayerhoff, D., Loebel, A., Geisler, S., Chakos, M., Koren, A., Jody, D., Kane, J., Woerner, M., Cooper, T., 1995. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. *Am. J. Psychiatry* 152, 698–703. <https://doi.org/10.1176/ajp.152.5.698>.
- Tannenbaum, C., Greaves, L., Graham, I.D., 2016. Why sex and gender matter in implementation research economic, social, and ethical factors affecting the implementation of research. *BMC Med. Res. Methodol.* 16, 1–9. <https://doi.org/10.1186/S12874-016-0247-7/TABLES/3>.
- Usall, J., Ochoa, S., Araya, S., Márquez, M., 2003. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. *Eur. Psychiatry* 18, 282–284. <https://doi.org/10.1016/j.eurpsy.2003.06.001>.
- Varo, C., Solé, B., Jiménez, E., Bonnin, C.M., Torrent, C., Valls, E., Lahera, G., Martínez-Arán, A., Carvalho, A.F., Miskowiak, K.W., Vieta, E., Reinares, M., 2020. Identifying social cognition subgroups in euthymic patients with bipolar disorder: a cluster analytical approach. *Psychol. Med.* 52, 159–168. <https://doi.org/10.1017/S0033291720001865>.
- Varo, C., Amoretti, S., Sparacino, G., Jiménez, E., Solé, B., Mar Bonnin, C. del Montejo, L., Serra, M., Torrent, C., Salagre, E., Benabarre, A., Salgado-Pineda, P., Salvatierra, I.M., Sáiz, P.A., García-Portilla, M.P., Sánchez-Gistau, V., Pomarol-Clotet, E., Ramos-Quiroga, J.A., Pacchiarotti, I., García-Rizo, C., Undurraga, J., Reinares, M., Martínez-Arán, A., Vieta, E., Verdolini, N., 2022. Emotional intelligence: a comparison between patients after first episode mania and those suffering from chronic bipolar disorder type I. *Psychol. Med.* doi:<https://doi.org/10.1017/S0033291721005122>.
- Verdolini, N., Borrás, R., Sparacino, G., Garriga, M., Sagué-Vilavella, M., Madero, S., Palacios-Garrán, R., Serra, M., Forte, M.F., Salagre, E., Aedo, A., Salgado-Pineda, P., Salvatierra, I.M., Gistau, V.S., Pomarol-Clotet, E., Ramos-Quiroga, J.A., Carvalho, A. F., García-Rizo, C., Undurraga, J., Reinares, M., Aran, A.M., Bernardo, M., Vieta, E., Pacchiarotti, I., Amoretti, S., 2022. Prodromal phase: differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood. *Acta Psychiatr. Scand.* <https://doi.org/10.1111/ACPS.13415>.
- Vidal, N., Brunet-Gouet, E., Frileux, S., Aouizerate, B., Aubin, V., Belzeaux, R., Courtet, P., D'Amato, T., Dubertret, C., Etain, B., Haffen, E., Januel, D., Leboyer, M., Lefrere, A., Llorca, P.M., Marlinge, E., Olié, E., Polosan, M., Schwan, R., Walter, M., Barteau, V., Bensalem, S., Godin, O., Laouamri, H., Souryis, K., Hotier, S., Pelletier, A., Drancourt, N., Sanchez, J.P., Saliou, E., Hebbache, C., Petrucci, J., Guillaume, L., Bourdin, E., Bellivier, F., Carminati, M., Meheust, J., Hennion, V., Francisque, H., Da Ros, N., Desage, A., Elkael, C., Gard, S., Hoorelbeke, F., M'bailara, K., Minois, I., Sportich, J., Boukhobza, L., Benramdane, M., Deffinis, B., Denat, S., Ducasse, D., Gachet, M., Molière, F., Nass, L., Tarquini, G., Cermolacce, M., Groppi, F., Moreau, E., Lescailier, L., Pastol, J., Vigliani, N., Cohen, R., Gross, G., Schwitzer, T., Wajsbrot-Elgrabli, O., Bougerol, T., Fredembach, B., Denoual, G., Bertrand, A., Pouchon, A., Bonny, G., Brehon, L., Durand, L., Feuga, V., Galliot, A.M., Kayser, N., Passerieux, C., Roux, P., Cussac, I., Dupont, M.A., Loftus, J., Medecin, I., Mazer, N., Portallier, C., Scognamiglio, C., Bing, A., Laurent, P., Llorca, P.M.M., Samalin, L., Fours, L., Lacelle, D., Pires, S., Doriat, C., Blanc, O., Bennabi, D., Nicolier, M., 2023. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: results from the FACE-BD cohort. *Eur. Neuropsychopharmacol.* 77, 67–79. <https://doi.org/10.1016/J.EURONEURO.2023.08.502>.
- Vieta, E., Berk, M., Schulze, T.G., Carvalho, A.F., Suppes, T., Calabrese, J.R., Gao, K., Miskowiak, K.W., Grande, I., 2018. Bipolar disorders. *Nat. Rev. Dis. Primers* 4. <https://doi.org/10.1038/NRDP.2018.8>.
- Viguera, A.C., Baldessarini, R.J., Tondo, L., 2001. Response to lithium maintenance treatment in bipolar disorders: comparison of women and men. *Bipolar Disord.* 3, 245–252. <https://doi.org/10.1034/j.1399-5618.2001.30503.x>.
- Wechsler, D., 1997. *Wechsler Memory Scale. The Psychological Corporation, Third Edition (WMS-III)*.
- Wechsler, D., 1955. *Wechsler Adult Intelligence Scale—Third Edition (WAIS-III)*. The Psychological Corporation.
- Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., 1978. A rating scale for mania: reliability, validity and sensitivity. *Br. J. Psychiatry* 133, 429–435. <https://doi.org/10.1192/bjp.133.5.429>.
- Zhang, B., Han, M., Tan, S., De Yang, F., Tan, Y., Jiang, S., Zhang, X., Huang, X.F., 2017. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. *Sci. Rep.* 7. <https://doi.org/10.1038/S41598-017-12027-W>.
- Zhang, X.Y., Chen, D.C., Xiu, M.H., De Yang, F., Haile, C.N., Kosten, T.A., Kosten, T.R., 2012. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. *J. Clin. Psychiatry* 73, 1025–1033. <https://doi.org/10.4088/JCP.11m07422>.